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Abstract
Pseudomonas aeruginosa vaccine development using dual-species whole cell and
subunit vaccines
Catherine Bell Blackwood
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen which can cause
severe, recurrent, and chronic infections. The pathogen is highly adaptable, and
pneumonia caused by it is associated with high morbidity and mortality, especially in
individuals with the genetic disorder cystic fibrosis. Antibiotic resistance amongst clinical
isolates of P. aeruginosa is steadily increasing, and multi-drug resistant strains are
prevalent. There is currently no vaccine available for commercial use against P.
aeruginosa. For these reasons, we sought to understand the immunity to P. aeruginosa
induced by whole cell vaccination and identify antigens for development of future subunit
vaccines. In this dissertation, we tested P. aeruginosa and Bordetella pertussis whole cell
immunization in parallel and identified unique correlates of protection for each. We next
characterized the cross-protective response induced by B. pertussis whole cell
immunization towards P. aeruginosa, in wild-type and CF murine models. We identified
that pertussis whole cell immunization was induced production of antibodies which bind
two P. aeruginosa proteins: GroEL and OprF. Finally, we expanded our previously tested,
iron-acquisition system targeting, peptide-based vaccination model to test three novel
antigens: FptA, PhuR, and HasR. Altogether, these data are a valuable next step in
formulation of a vaccine for P. aeruginosa that can be further optimized for efficacy and
considered for clinical trial testing.
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Chapter 1. Introduction

1

1.1

History & Intro to Vaccines

Vaccines are a vital tool in the medical field for prevention of infection by deadly
pathogens, and have saved countless lives world-wide. One of the first formulations of a
vaccine was Edward Jenner’s use of cowpox to prevent smallpox infection and disease
(1). This discovery birthed the field vaccinology, which has continued to develop and
deepen in the centuries since its inception. Variolation, or inoculation, prevented a more
severe infection from occurring later. This practice then evolved into what we would refer
to now as a live-attenuated vaccine (LAV). LAVs contain a weakened version of the
pathogen that cannot cause severe infection, but is similar enough to still induce
protective immunity. The discoveries made by Louis Pasteur and Robert Koch a century
later, that pathogens could be carefully but precisely killed, resulted in the development
of inactivated vaccines to prevent cholera, typhoid, and plague (2). In the 1920s, subunit
vaccines containing only the toxoids of diphtheria and tetanus were introduced. A hundred
years later, in 2020, the knowledge within the field of vaccinology has allowed the world
to begin its recovery against the world-wide COVID-19 pandemic. Vaccines have, and
will continue to, save lives.
1.1.1 Components & Formulation
The exact formulation of a vaccine is as unique as each pathogen, but they contain a
combination of two main active components: antigen and adjuvant (3). Antigens are the
bacterial or viral components towards which the immune response is targeted, and B and
T cell recognize. The exact antigens included depend on the virulence factors that are
involved in disease manifestation. Preparations of whole bacteria for whole cell vaccines
contain hundreds to thousands of proteins, but subunit vaccines typically contain less
than ten (4). In the case of toxin-mediated infections such as diphtheria and tetanus,
toxoid antigens are sufficient to induce protection from disease. In other cases, virulence
factors, adhesins, or outer membrane components induce protection. Therefore,
selection of antigens for any subunit vaccine must be done carefully and logically (5, 6).
There are two main groupings of subunit vaccine antigens: non-protein and protein. Nonprotein antigens typically involve use of outer membrane polysaccharides, with the goal
of inducing production of opsonizing antibodies and complement deposition. The
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pneumococcal polysaccharide vaccine, or PPSV23, contains 23 serotypes of the
pathogen’s polysaccharide (7). Similar non-protein targets such as LPS and alginate are
abundantly produced by P. aeruginosa, but there are significant caveats when
considering their use in a vaccine. LPS is widely variable among clinical strains of the
pathogen, and there are at least a dozen serotypes (8). Further, it is difficult to establish
a long-lasting immune response towards non-protein antigens such as polysaccharides,
due to lack of T cell interaction with B cells to induce germinal center reactions, somatic
hypermutation, and class-switching (9). However, antigens that are designed based on
bacterial or viral proteins are able to trigger B cells to undergo somatic hypermutation and
class switching in response to T cell stimulation. Protein antigens can be formulated as
whole proteins, peptides, or protein-encoding RNA (10–12).
An important addition to subunit vaccines is the adjuvant. Adjuvants are components in a
vaccine which boost the response towards the antigens, either by causing a depot effect,
inducing production of cytokines, or interacting with immune cells to increase antigen
recognition (13). WCVs typically contain “natural adjuvantation” because they include
bacterial products such as LPS, which stimulate TLR recognition. Subunit vaccines
typically do not contain significant levels of endotoxin, and may need exogenous or
synthetic adjuvant added to the formulation to improve immune recognition (14). Alum
was the first adjuvant developed, in 1926 by Alexander Glenny, and is still the most
common adjuvant to be used in vaccines approved for use in humans (9). Aluminum
hydroxide, specifically, is used in DTaP, TDaP, Hepatitis A, Hepatitis B, HPV (Gardasil),
and Pneumococcal (Prevnar-13, -23) vaccines (15). By adsorbing antigens to alum salts,
they are retained in the tissue for longer after injection, a phenomenon known as a “depot
effect” and the alum is able to induce inflammation in the tissue and recruitment of
macrophages to phagocytose the antigen (9, 16). Alum is also associated production of
IL-1ß and IL-10, which contributes to the induction of a primarily Th2 response (17–19).
The expansion of the adjuvant repertoire has been one of the more recent advancements
in the field of vaccinology, including design of adjuvant that are better suited for use in
the mucosa, and trigger Th1/Th17 responses (20, 21). Only in the last decade have novel
adjuvants begun receiving approval for use in humans, and the vast majority are variants
of the alum adjuvant. AS04, which includes an adsorbed combination of aluminum salt
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and MPL (3-O-desacyl-4’-monophosphoryl lipid A), is used in the human papillomavirus
vaccine, Cervarix (22). By combining two adjuvant compounds, AS04 induces a
synergistic response to further extend the inflammatory response at the site of injection
and increases the number of antigen-carrying dendritic cells and antibody titers towards
the antigen (23). Other adjuvants such as MF59, an oil-in-water emulsion, and
unmethylated CpG DNA fragments, are also approved for use (24). Adjuvants are not
typically tested in humans until they are part of a vaccine formulation, but there is a wide
variety in pre-clinical testing. One adjuvant that has not yet been approved for use in
humans, but has shown promising results in laboratory testing, is curdlan. Curdlan is a β1,3-glucan molecule produced by Alcaligenes faecalis, which can form a “curdled” gellike compound under heated, basic conditions (25). In this form, the gel can be mixed with
antigens for vaccination and administered, resulting in a similar depot effect as alum.
Unline alum, which induces a primarily Th2-type immune response, curdlan induces
dendritic cell polarization and a Th1/Th17 type response (20, 26).
Adjuvants can also help to increase immunogenicity of vaccines that are administered to
a mucosal surface, including by the oral, nasal, and suppository delivery (27–29).
Mucosal administration of vaccines, which more efficiently induces a mucosal immune
response than traditional intramuscular immunization, often requires adjuvantation to
increase immunogenicity at the site of immunization (30). Mucosal immunity is of
particular importance for pathogens that infect in the respiratory tract, and has been
investigated in the context of both P. aeruginosa and B. pertussis (26, 31, 32).
1.1.2 Correlates of Protection
Upon delivery of a vaccine into host tissue, foreign antigens are detected and
phagocytosed by innate immune cells. Antigen presenting cells, such as dendritic cells
and macrophages, then display epitopes on major histocompatibility complexes (MHC)
to induce an adaptive immune response. The exact mechanism of protection induced is
unique to each pathogen, and depends on the interplay of cells and cytokines that induce
the adaptive response. As a result, unique correlates of protection (CoP), or biological
factor that can be statistically correlated to immunity, can be identified for each vaccine.
One of the most common CoPs is the production of anti-pathogen antibody titers, but
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there can be cellular CoPs as well (33). It is important to understand the CoPs for a
pathogen when designing a vaccine, because these markers can sometimes be used to
predict vaccine efficacy.
1.2

Bordetella pertussis

Bordetella pertussis is a Gram-negative bacterium that is a causative agent of the
respiratory infection whooping cough (34). The first written record of the infection was in
Paris in 1578, but B. pertussis was identified in 1906 by the Belgian scientists, Jules
Bordet and Octave Gengou (35). Whooping cough has historically been a major pathogen
causing disease and death in infants, killing five out of every thousand children at the time
it was identified (36). The bacteria is spread via respiratory droplets by cough, and is
highly contagious (Figure 1). Bacteria then adhere to ciliated epithelial cells using the
adhesins pertactin and filamentous hemagglutinin, and colonize the host (37). This is the
incubation phase of pertussis, and lasts one to two weeks after exposure (38). Next,
during the catarrhal stage, patients may begin to exhibit symptoms of a minor respiratory
infection. It is during the catarrhal stage when paroxysms, or violent “whooping” coughs,
may begin. If unvaccinated, disease progression is especially dangerous.
B. pertussis secretes toxins to inhibit the immune response. Its namesake toxin, pertussis
toxin, is an AB5-type toxin, which inhibits recruitment of neutrophils and macrophages to
the site of infection (39). Unable to taxis into the infected tissues, leukocytes are then
trapped in the circulatory system, causing leukocytosis. Another major secreted toxin of
B. pertussis is adenylate cyclase toxin, which has hemolytic function, and is required for
establishment of infection (40). The cause of cough remains unknown (41). The
combination of these two major symptoms, violent cough and leukocytosis, are the
primary contributors to the morbidity and mortality associated with pertussis infection (42).
A large study of pertussis infection in humans occurred in the 1990s in Germany, where
they observed the typical symptoms of whooping cough in unvaccinated and vaccinated
patients (43). They found that more than 90% of unvaccinated patients exhibited the
paroxysmal cough, nearly 80% presented with the “whooping” cough, and 70-75% had
lymphocytosis or leukocytosis. More rarely, there are neurological complication such as
seizures, associated with pertussis infection.
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1.2.1 Pertussis vaccines
Vaccine development for pertussis occurred rapidly in the years after the pathogen was
identified. By the 1920s, formalin-inactivated cultured B. pertussis was formulated as a
vaccine, and quickly shown to be efficacious (2, 34). In the years following, more versions
of this inactivated whole cell vaccine were developed, and cases steadily dropped. To
this day, versions of the whole cell pertussis vaccines are still used in some parts of the
world, because of their stability when lyophilized and high rates of efficacy. In the United
States the acellular pertussis vaccines (DTaP and Tdap) have been used since 1996.
Since that time, pertussis incidence has steadily risen, likely in part to reduced vaccine-

Figure 1. Bordetella pertussis pathogenesis and vaccine antigens Bordetella pertussis
pathogenesis and vaccine antigens. B. pertussis is spread by respiratory droplet. Using
adhesin factors pertactin and filamentous hemagglutinin, it adheres to ciliated
respiratory epithelial cells. B. pertussis secretes toxins to inhibit immune cell infiltration
to infected tissue, causing the hallmark symptom, leukocytosis.
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induced memory and circulating strains B. pertussis which no longer produce the antigens
in the vaccine (37).
1.2.1.1 Whole cell pertussis vaccines
Whole cell pertussis vaccines contain killed or inactivated B. pertussis bacterial cultures.
One of the first reports of successful formulation of a whole cell vaccine preventing
pertussis infection was in 1926 (2). In the United States, vaccination against B. pertussis
has almost always occurred in combination with vaccination against diphtheria and
tetanus. DTP (Diphtheria, Tetanus, Pertussis) vaccine was widely adopted in the US by
the mid 1940s, and greatly reduced the prevalence of pertussis infections in children.
However, differences in formulation of the whole cell vaccine, for example variation in
growth condition or inactivation method, greatly impacted the efficacy of the whole cell
vaccines (44). Subsequent data have been generated to closely examine the protein
composition of pertussis whole cell vaccines, and highlight that the composition of this
whole cell vaccine have changed with different formulations (45). To improve consistency
of the vaccine, the WHO developed a standard pertussis vaccine, to which all other
formulations should be compared (46, 47). The measurements used to compare vaccine
batches also vary, which contributes to inconsistencies with formulations world-wide.
Additionally, there were concerns about the reactogenicity of pertussis whole cell
vaccines. Reactogenicity refers to the immediate inflammatory response that can occur
following vaccination, including swelling and redness at the site of injection and systemic
responses such as headache, myalgia, and fever (48).
1.2.1.2 Acellular pertussis vaccines
The acellular vaccines for pertussis are utilized primarily in higher-income countries, and
depend on cold-chain storage. The exact antigens contained in the vaccine varies
between countries, but typically contains one to five antigens. In the United States, the
two pertussis vaccines used are DTaP and Tdap. Both of these vaccines contain antigens
for diphtheria, tetanus, and pertussis. The pertussis antigens contained are detoxified
pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae. The antigens are
adsorbed the adjuvant alum (24). These vaccines were adopted rapidly in the 1990s in
the US, and prevented severe pertussis infection in children, and had lower incidence of
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inflammatory side-effects associated with the whole cell pertussis vaccines (49). Because
of this, the acellular pertussis vaccines became the standard immunization used in the
US. However, since it’s adoption there has been a steady increase in the incidence of
pertussis in the US, resulting in an outbreak in 2012 (50). Additionally, it has been
demonstrated that the acellular pertussis vaccine induces shorter term memory than the
whole cell pertussis vaccine and that there are vaccine-escape strains of pertussis
present at increasing levels (37). Taken together, these data indicate that next generation
pertussis vaccines need to be studied and developed, to prevent further increase in
pertussis incidence.
1.3

Pseudomonas aeruginosa

Pseudomonas aeruginosa is an opportunistic pathogen that has substantial disease
burden in patients with cystic fibrosis (CF) and other immunocompromising conditions
such as burn wounds, cancer, or diabetes. Not only is P. aeruginosa able to cause severe
infections, but it is also highly antibiotic resistant, making it difficult to treat (51). The
necessity for a vaccine against Pseudomonas aeruginosa has been recognized for
decades (52), particularly within the CF community.
1.3.1 Bacteriology & epidemiology
Pseudomonas aeruginosa was first described as a pathogen in the 1880s by Carle
Gessard, who described it as a pathogen which caused a blue-green colored pus in
wounds (53). In 1916, it was again described by Dr. Leonard Freeman, named Bacillus
pyocyaneus, a rod-shaped bacterium that caused both acute and chronic infections,
including a systemic disease associated with “green pus” (54). The characteristic bluegreen pigmentation is due to extracellularly secreted toxin, virulence factor, and pigment:
pyocyanin (55).
P. aeruginosa is a Gram-negative rod-shaped bacterium capable causing infection in
plants, agricultural animal, and human hosts (56, 57). It is highly adaptable to grow in
different nutrient conditions, thanks to its relatively large, 6.3 million base pair genome
(58). This allows it to survive in nearly any natural environment, including in water, soil,
and plants, as well as human-made environments (59). P. aeruginosa survives in hostile
environments seemingly devoid of any nutrient, including in hot tubs, on hospital surfaces,
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and patient care equipment (60). The environmental prevalence of P. aeruginosa makes
it nearly impossible to avoid exposure to the bacterium. While the bacterium can be found
amongst non-pathogenic microflora on the skin and mucosal surfaces of some healthy
people, it is more frequently studied and isolated in the context of actively causing disease
(61). P. aeruginosa has repeatedly been classified as a significant threat to public health
by the Center for Disease Control (CDC) (62, 63).
Nearly any tissue can be infected by P. aeruginosa. Keratitis, pneumonia, bacteremia,
meningitis, otitis media, and urinary tract infections are some of the commonly associated
infections (59). However, this bacterium thrives in individuals with immunosuppression or
in previously damaged tissue, such as a burn, trauma, or surgical wound (64, 65). It can
also be readily found in implant or medical equipment associated infections, which can
be contaminated by P. aeruginosa in the hospital. Frequently, P. aeruginosa cause
ventilator associated infections, which occur when the ventilators are colonized with P.
aeruginosa that is then directly fed into the lungs of patients. Populations at high risk for
P. aeruginosa infections include individuals who are immunocompromised, have recently
undergone chemotherapy, have severe burn or tissue wounds, and individuals with
chronic respiratory issues such as COPD and cystic fibrosis (60, 66). In patients who are
predisposed by some respiratory disease, P. aeruginosa causes recurrent or chronic
infections (67, 68).
1.3.2 Cystic Fibrosis
P. aeruginosa respiratory infections are of particular relevance and importance in the
context of the genetic disorder cystic fibrosis (CF). CF is caused by mutations in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene. There are hundreds
of mutations that can cause CF, but patients typically have only one or two. These
mutations reduce or completely inhibit function of the protein systemically. The types of
mutations that cause this malfunction are split into six classes that describe the type of
malfunction present, including lack of protein altogether, decreased production, stability,
or function of the protein, incorrect protein folding (69, 70). The most common CF-causing
mutation is a deletion of phenylalanine 508 within the CFTR gene (71). F508 causes
defective production of the CFTR protein, resulting in its retention in the endoplasmic
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reticulum and degradation (69, 72). The CFTR mutations within these categories all result
in the same functional outcome for patients: a disruption in ion balance in all cells.
Disrupted ion balance results in thickened mucous on the surface of epithelial cells, which
causes permanent damage to cells and tissues over time. Thickened mucous is
particularly damaging to the function of epithelial cells, such as those that line the
respiratory and digestive tracts (73). One of the primary symptoms associated with CF
disease is inhibited respiratory epithelial cell functions such as ciliary action, which predisposes patients to infection in their respiratory tract. Once colonized, it is difficult or
impossible for the cilia in the respiratory tract to physically remove the bacteria. The
airway of CF patients is chronically inflamed, chronically infected, and respiratory
infections contribute to the death of a majority of these patients (74). By adulthood, most
people with CF are or have been colonized by P. aeruginosa, and as recently as 2019,
more than 40% of all CF patients were colonized (75).
Recently, there has been significant progress made in gene therapies for cystic fibrosis
patients. Because the class-II mutation types, which include mutations that impair protein
processing, are held by 88% of all CF patients (70), small molecule therapeutics are
primarily developed for this type of mechanism. Initially it was thought that gene
replacement therapies would be the end of CF, but due to technical difficulties and ethical
concerns associated with altering the genes of every cell within a body, such a therapeutic
is not currently feasible. One of the first compounds that was approved for use in CF
patients is the drug Kalydeco, which was designed to rescue the G551D missense
mutation found in 5% of people with CF but has shown efficacy even in patients with
different mutations that have close functional relatedness (76–78). Additional
therapeutics have been developed to target other CFTR mutation types, as well as
combination therapeutics. In 2019, a triple-combination CFTR modulator, Trikafta
(elexacaftor/tezacaftor/ivacaftor) was approved for use.

As a result of these

advancements, more than 80% of CF patients are now eligible for CFTR modulating
therapy, which increases their lifespan and quality of life (75). However, there is conflicting
evidence about how the therapeutics affect patient microbiology and issues with disease
associated infections (75). Ivacaftor, one of the compounds in Trikafta, improved overall
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health outcomes, but has no detectable impact on P. aeruginosa infections, as far as a
year into treatment (78, 79).
Despite these advances in the care of CF patients, P. aeruginosa remains a significant
health threat. By the time CF patients reach adulthood, they are more likely to be
colonized by P. aeruginosa than any other pathogen, including S. aureus, MRSA, H.
influenzae, and B. cepacia complex species (75). Colonization with multi-drug resistant
P. aeruginosa is also increasing (63, 75). Taken together, these data indicate that while
there are available therapeutics for patients with CF that can improve their genetic
disease phenotype, there is still a significant need to develop means to prevent P.
aeruginosa infection in this population.
1.3.2.1 Animal Models for Cystic Fibrosis
The CFTR gene was identified and sequenced in 1989 and shortly after, laboratory
models for CF disease were developed (80). There are now CF-modeling systems in
mice, rats, ferrets, pigs, and zebrafish (81–84). Animal models serve as a valuable source
of information on early formation of disease, which would be unethical to study in children
with CF. Each of the models has advantages, depending on the organ or disease
phenotype of interest (83). While mice and rat models are the most used, the ferret and
pig models for CF have allowed for investigation of therapeutics in large-tissue (85). Some
of these models utilize mutations or deletions of the CFTR gene, to mimic those found in
humans (86). CFTR mouse models are phenotypically different from the disease seen in
humans, and have chronic intestinal obstructions, but less CF-like respiratory symptoms
(87). CFTR mouse models fail to recapitulate the mucous plugging or spontaneous airway
inflammation that is seen in humans with CF. Newer murine CF models, such as the βENaC mouse model were developed to better mimic the human CF phenotype (87, 88).
In the β-ENaC model, mice have a transgenic alteration to over-express an epithelial
sodium channel (Epithelial Na Channel), and they display an increased production of
mucous, mucous plugging in the airway, and some of the immune phenotypes observed
in humans (Figure 2, adapted from (87)).
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Figure 2. The β-ENaC mouse model for cystic fibrosis. Transgenic β-ENaC mice
overexpress the epithelial sodium channel specifically in the respiratory tract. These
mice present similar respiratory phenotype to that observed in human cystic fibrosis
patients, including mucous plugging, chronic neutrophilia, and eosinophilia. Figure
based on Zhou et al, 2011.
1.3.3 Typical treatments & antibiotic resistance
Treatment of P. aeruginosa infections is complicated by the prevalence of drug-resistant,
and multi-drug resistant strains in circulation (89–91). This resistance comes from both
intrinsic antibiotic resistance mechanisms and the evolution of resistance due to constant
exposure to antibiotics. P. aeruginosa has low cell membrane permeability, and during
infection increases expression of efflux pumps and β-lactamase, and decreases
expression of surface porins, effectively stopping antibiotics from entering the cell, and
swiftly removing or metabolizing any that do. In combination with the production of biofilm
that acts as a physical barrier, and a reduced growth rate, the bacterium evades both
immune and medical arsenals (68). In addition to these strong intrinsic defenses, P.
12

aeruginosa has the ability to acquire further antibiotic resistance mechanisms by genetic
mutation or horizontal gene transfer. In laboratory studies, P. aeruginosa quickly becomes
resistant to the fluoroquinolone ciprofloxacin, the aminoglycoside tobramycin, and the βlactam antibiotics ceftazidime, meropenem, and piperacillin in combination with the βlactamase inhibitor tazobactam (92). Those five antibiotics are among the most frequently
clinically used, and these findings highlight that antibiotic resistance is a significant issue
to consider when treating P. aeruginosa infections. For these reasons, it has been a
priority in the field of P. aeruginosa microbiology to develop immunotherapeutics, such as
vaccines and monoclonal antibodies to prevent or treat infections (93).
1.3.4 Vaccination against P. aeruginosa
Given the prevalence of antibiotic resistance amongst clinical strains of P. aeruginosa
and risk associated with infection, it may come as no surprise that a vaccine to prevent
P. aeruginosa has been tested in the laboratory and clinic. Indeed, there have been
numerous attempts at formulation of vaccination or other immunotherapy against the
bacteria, but none has ever been approved for use in humans in the US (94).
1.3.4.1 Whole cell P. aeruginosa vaccines
Similar to whole cell vaccines developed for other pathogens, whole cell vaccines for P.
aeruginosa contain killed or inactivated P. aeruginosa culture. The major advantage of
whole cell vaccines is that they contain multiple antigens to the immune system and that
they are immunogenic. In the case of P. aeruginosa, they have not been approved for
use in humans because of high reactogenicity and toxicity (95). An oral, inactivated whole
cell P. aeruginosa vaccine known as Pseudostat was tested in humans in the early 2000s,
and was immunogenic, but some patients had side effects following immunization (64,
96). Another concern regarding whole cell Pseudomonas vaccines is that the vaccine will
not induce sufficient protection against serotype heterologous strains of the bacterium.
As a result, whole cell Pseudomonas vaccines are unlikely to be approved for human use,
but serve a crucial role in studying adaptive immunity from the bacterium.
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1.3.4.2 Major virulence factors and their use as vaccine antigens
When identifying and designing antigens for vaccination against P. aeruginosa, it is
important to understand the major virulence factors and antigens which have been tested
historically (Figure 3). A recurring theme within vaccine development for P. aeruginosa is
that a single antigen is not sufficient to induce broad protection from infection. This is in
part a result of the adaptability of P. aeruginosa to produce varied antigens. In order to
design the next generation of vaccines for lab and clinical testing, it’s important to have a
base understanding of the previous attempts at vaccination using the virulence factors of
P. aeruginosa.

Figure 3. Major virulence factors and antigens for P. aeruginosa. Pseudomonas
aeruginosa is a motile bacterium which utilizes its flagella and pili to also bind to
eukaryotic cells. P. aeruginosa uses several secretion systems to secrete enzymes and
toxins into the environment and inject toxins into competing bacteria as well as target

eukaryotic cells. It also utilizes biofilm formation to colonize and cause chronic infection.
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1.3.4.2.1 Alginate
P. aeruginosa produces the exopolysaccharides alginate, Psl, and Pel. Alginate is a
secreted lipopolysaccharide and an important component of the biofilms formed by P.
aeruginosa. Alginate is also known as mucoid exopolysaccharide (MEP), and forms a
protective barrier between the bacterium and the immune system of the infected host,
inhibiting expulsion by cilia, and preventing opsonization or phagocytosis (97). Initially, it
was disputed if an immune response could even be mounted against the polysaccharide,
but alginate-specific antibody responses were soon characterized in CF populations (98–
101). Not only were anti-alginate responses detected in humans, but the level of response
positively correlated with infection by mucoid strains, indicating that in response to higher
exposure, more of the antibodies were produced. This development led to application of
alginate-antibody detection by ELISA as a method for diagnosis (99). Further supporting
its use as an antigen, patients with highest titers against alginate were detected in people
not chronically colonized, indicating they may prevent prolonged infection (102).
Following these observations, there were several experimental laboratory recapitulations.
Vaccination of laboratory mice or rabbits with purified sodium alginate stimulated an
antibody response, induced opsonization and protection from infection, even by
heterologous strains with distinct MEP antigens (103). Vaccination in combination with
other, more antigenic, components improves this response. For example, response to
alginate can be increased by vaccination with more immunogenic P. aeruginosa product,
Exotoxin A (104). Similarly, conjugation of P. aeruginosa alginate to common carrier
proteins keyhole limpet hemocyanin (KLH) or tetanus toxoid boosted response, and led
to increased antibody titers in animals compared to animals vaccinated with non-carrierconjugated proteins (105, 106). These antibodies can enhance C3 deposition, increase
opsonic killing, and improve protection from strains used in vaccination and heterologous
strains (103, 105, 107). However, use of alginate in humans has not been efficacious,
potentially because pre-existing alginate antibodies which are non-opsonic prevent
development of opsonizing antibodies (94)

15

1.3.4.2.2 LPS
The outer leaflet of P. aeruginosa contains highly toxic lipopolysaccharide (LPS). P.
aeruginosa LPS is a major virulence factor for the bacterium, and consists of Lipid A,
Core, and O-antigen (108). LPS provides the structure for the outer membrane of the
bacterium, stimulates a large portion of the immune response following exposure to
bacteria, and is known as endotoxin because of this. P. aeruginosa lipid A is recognized
by toll-like receptor-4 (TLR-4) and is strongly proinflammatory (109). LPS is produced in
two forms in P. aeruginosa: smooth and rough. Smooth LPS is expressed during acute
infections, has high abundance of long O side chains, and helps prevent
opsonophagocytic and complement mediated killing. Rough LPS has short, few or no,
side chains, and is found during chronic infections, helps to evade the host immune
system (110). Strains of P. aeruginosa that produce less or no LPS have reduced
virulence (111, 112).
In the case of P. aeruginosa, there is a high number of serotypes, or groupings based on
serum reactivity against the O-antigen. The most complete record of serotypes of P.
aeruginosa was developed by the International Antigenic Scheme (IATS), which reported
20 unique serotypes of P. aeruginosa found in clinical strains (113). As a result, vaccines
containing one serotype of P. aeruginosa LPS may not produce an immune response to
heterologous strains (114). Two multivalent LPS vaccines have been tested clinically, a
heptavalent LPS vaccine called Pseudogen and a 16-valent vaccine called PEV-01, (115,
116). While they both improved outcomes for patients infected with P. aeruginosa, they
did not meet the requirements for routine clinical use because of the toxicity associated
(116). Others have observed that certain serotypes are immunogenic whereas others are
inhibitory of the immune response (117). The combination of complex diversity within the
components of LPS and the complexity associated with inducing immunological memory
towards polysaccharides, has resulted in difficulty using LPS as a vaccine antigen for P.
aeruginosa. Rather than vaccinating with the potentially toxic LPS variants, it may be
better to identify conserved antigens expressed by P. aeruginosa of each serotype (118,
119).
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1.3.4.2.3 ExoA
Exotoxin A is an ADP-ribosylating exotoxin produced by P. aeruginosa, which has
structurally similar domains to diphtheria toxin (120). It is arguably the most toxic
component of P. aeruginosa, and inhibits production of proteins in eukaryotic cells,
making it one of the major virulence (121). Exotoxin A can be detected in infected tissues
of animals but does not appear to be circulating in the blood of infected hosts. People
who survive Pseudomonas infection and become convalescent have increased anti-toxin
antibody titers compared to acutely infected or uninfected individuals (122). Not only is
ExoA immunogenic, but infection by an ExoA producing strain can be fatal if the patient
does not produce antibodies towards it (123). However, ExoA has not seen much success
as a solo antigen for vaccination against Pseudomonas, because anti-ExoA antibodies
do not help with clearance of the bacterial itself (124).
To improve ExoA vaccine formulations groups have explored the combination of ExoA
with other immunogenic products of Pseudomonas. One study showed that fusions of
ExoA to flagella protein induced production of opsonizing antibodies and protection from
systemic infection, but this function was dependent on the inclusion of the flagellar protein
(125). Similarly, a chimeric protein vaccine containing type IV pili and a non-active version
of ExoA, administered to rabbits, inhibited adherence of the bacteria to eukaryotic cells
and also increased neutralization of the toxin (126). However, a conjugate formulation of
nontoxic ExoA and alginate, similarly able to induce toxin neutralizing antibodies in
rabbits, did not elicit this response in mice, the most common model organism for
preclinical vaccine trials (104). Other formulations prevented sepsis, corneal damage, or
development of lung lesions or tissue damage (127–130), depending on the model in
which it is tested. Interestingly, some antigens have immunogenic properties, including
ExoA. Because the protein itself is immunogenic, it has also been used as a carrier protein
for S. aureus polysaccharides, helping to recruit T cell involvement in response to the
vaccine (131). Taken together, these studies drive home two key conclusions: ExoA is a
potent virulence factor, and vaccination using this protein should be considered in future
polyvalent vaccine preparations.
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1.3.4.2.4 Outer Membrane Proteins
The outer membrane of P. aeruginosa is decorated with outer membrane proteins,
secretion systems, pili, and a polar flagellum. These proteins are exposed on the surface
of the cell, where they can be recognized by the immune system, and may induce
serotype independent protection (132, 133). Here, I will describe some of the outer
membrane protein antigens that have been tested as vaccine antigens for P. aeruginosa.
1.3.4.2.4.1 Secretion System Components
Secretion systems of pathogenic bacteria have long been known to be virulence factors
in the most pathogenic of species, P. aeruginosa included. Secretion of toxins allow
pathogenic strains to attack and weaken host eukaryotic cells during infection, as well as
competing bacteria. As a result, it has been hypothesized that vaccinating against the
secretion systems and their products could inhibit the pathogenesis of the bacteria. P.
aeruginosa expresses five secretory systems (types I, II, III, V and VI) to release a wide
variety of toxins and enzymes that attack the host (64). The type I secretion system is an
ABC transporter and is responsible for secretion of enzymes to degrade host cells, and
heme acquisition proteins (134). A type II secretion system is responsible for secretion of
virulence factors including ExoA, phospholipase C, and elastases, which are all involved
in damaging host tissues and cells (124, 128, 135–137). Type III secretion systems use
a needle-like structure to inject effectors into target cells (65, 138). The type III secretion
system component PcrV is a protective antigen for immunization in mice, and anti-PcrV
IgY antibodies protect against Pseudomonas aeruginosa infection in both acute
pneumonia and burn wound models (139, 140). Another type III secretion system
component, PopB, is an antigen known to induce strong Th17 response, and induces a
protective immune response in mice, when used in combination with PcrV (141, 142).
Because these proteins are surface exposed and have a role in virulence, targeting them
for degradation by the immune system may have double benefit: clearing bacteria and
inhibiting pathogenesis (143). The secreted products of type III secretion systems,
including ExoS, ExoT, and ExoU toxins also have an important role in pathogenesis, and
use cytotoxicity to help with dissemination of the bacteria (138). Type V secretion system,
or autotransporter, of P. aeruginosa secretes the esterase EstA, which is required for
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rhamnolipid production (144, 145). Several secretion system proteins have been tested
for antigenicity, but PcrV and PopB have been the most -successful to date (146). Future
multivalent P. aeruginosa vaccine formulations could consider addition of these antigens,
and study them as a model for effective immunization.
1.3.4.2.4.2 Flagella & Pili
P. aeruginosa flagella and pili are crucial for the pathogen’s ability to colonize and infect
hosts. They are involved in both the motility of the bacterium and in adhesion to host cells.
Flagellar proteins, in particular FliC has been investigates as an antigen for vaccination
against P. aeruginosa since the early 1990s (64). While it was initially promising, phase
III trials using a bivalent flagella vaccine revealed that patients were still infected by P.
aeruginosa after vaccination, by strains of P. aeruginosa that expressed flagellar variants
not contained in the vaccine (147).
The P. aeruginosa pilin protein is secreted by type IV secretion system, and is used to
adhere to eukaryotic cells (148, 149). Purified pilin is highly immunogenic and activates
murine inflammasome (148). A study of a bivalent pili and O-antigen vaccine resulted in
O-antigen specific protection, indicating that rather than using pilus protein as an antigen,
it could be a viable adjuvant for future P. aeruginosa vaccine candidates (150).
1.3.4.2.4.3 OprF
The most abundant non-lipoprotein on the surface of P. aeruginosa’s membrane is a
nonspecific porin: OprF. It is responsible for many functions and required for full virulence
of the pathogen, which makes it a prime target for immune recognition. OprF is an antigen
that is readily recognized by the immune system, and has been shown to interact with
innate immune cells. Neutrophils have an important role in fighting P. aeruginosa infection
(151–154). OprF can induce neutrophils to undergo NETosis (neutrophil extracellular
trap-osis) and is also readily degraded by neutrophil elastase (155, 156). There has also
been research focused on dendritic cells, which are an important antigen presenting cell
type. Adoptive transfer of DCs pulsed with P. aeruginosa OprF to naïve animals induced
a protective response to injection (157).
Traditional immunization against OprF has also been examined. There are numerous
articles regarding structure and function of this OmpA family surface protein, which is still
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not fully understood (158–161). OprF vaccines have been tested alone and in
combination with other antigens. OprF purified from polyacrylamide gel was protective in
a model of intramuscular rat immunization, and the rats produced antibodies that would
bind heterologous strains of P. aeruginosa (162, 163). DNA vaccine targeting OprF was
sufficient to induce antibody (mostly IgG1) towards OprF protein and opsonize P.
aeruginosa. However, the authors suggested that OprF should be combined with other
antigens that are known to be immunogenic (164). Multi-component subunit vaccines
containing OprF have also been tested. Gilleland et al. observed that a combined OprF,
elastase, ExoA vaccine was protective against a model of agar-bead instilled P.
aeruginosa infection in rats (162). The vaccines prevented pulmonary lesions, but they
did not observe increased protection compared to vaccination with OprF alone (128). A
live-attenuated vaccine using Salmonella that expressed recombinant P. aeruginosa
OprF and OprI, administered orally with a systemic booster induced strong IgA and IgG
in the airway (165). The authors observed that the combination of routes of immunization
induced stronger protection than use of either route alone. A recombinant OprF–OprI
protein vaccine, adsorbed to and adjuvanted with alum, was clinically tested, well
tolerated, and immunogenic in human volunteers (116). Patients all had increasing
antibody titers over time, and specifically produced the opsonizing antibody IgG1, but
protection from future infection was not quantified. Further, OprF induces immunity from
heterologous strains. Taking all of these trials together, it is clear that OprF is a highly
immunogenic component of the outer membrane and could be an antigen to consider for
future formulations of subunit P. aeruginosa vaccines.
1.3.4.3 Other important virulence factors
P. aeruginosa utilizes several other virulence factors including pyocyanin, quorum
sensing molecules, rhamnolipids, protease and phospholipase enzymes, and secreted
toxins. Pyocyanin is one of the pigments of P. aeruginosa, and provides the typical bluegreen color associated with the bacteria. Pyocyanin is also toxic to eukaryotic cells and
acts as a quorum sensing molecule that can help to regulate biofilm formation (55). P.
aeruginosa uses four quorum sensing systems, Las, Rhl, PQS, and IQS, to regulate
expression of rough or smooth LPS, flagella, biofilm, and nutrient acquisition systems (64,
166, 167). Rhamnolipids and other toxic enzymes, including alkaline protease and
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elastase, are used to inflict tissue damage to epithelial cells (168). Damage to eukaryotic
cells in the infected tissue benefits the bacteria in two main ways: preventing the
eukaryotic cells from clearing the infection, and breaking down cells to provide nutrition
for the bacterial colonization. Pseudomonas aeruginosa utilizes a variety of tools to
acquire and sequester nutrients, in order to outcompete other bacterial and fungal species
in encounters. Nutrients, such as carbohydrates, metals, and ions are acquired, and can
then be sequestered in the cell or in outer membrane vesicles, preventing access to them
by other bacteria in the environment. One nutrient of interest is iron, which is scarce in a
normal, healthy lung environment, but is present at much higher concentrations in the
lungs of people with cystic fibrosis, a genetic disorder that predisposes individuals for P.
aeruginosa infection. Acquisition of ferric iron (Fe3+) is required to cause murine
pneumonia (169). Because it is an important nutrient for growth and virulence, but is
limited in the environment and tissues where P. aeruginosa is commonly found, the
bacterium utilizes several mechanisms to acquire the metal.
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1.4

Dissertation Objective

Development of a vaccine for Pseudomonas aeruginosa could prevent thousands of
antibiotic resistant infections each year. In this work, we aimed to deepen the
understanding of immunity against P. aeruginosa and develop pre-clinical vaccine
candidates. In chapter two, we examined the protective immune response induced by
mucosal whole cell immunization against either P. aeruginosa or B. pertussis. By studying
vaccination and infection by these pathogens in parallel, we were able to directly compare
immunity and identify correlates of protection. In chapter three, we explored the nonspecific effects of B. pertussis whole cell immunization to induce a protective response
against P. aeruginosa. We used immunoprecipitation and mass spectrometry to further
characterize the P. aeruginosa antigens targeted by cross-reactive B. pertussis
immunized animals. The antigens identified can be used in future formulations of subunit
vaccines for P. aeruginosa. In chapter 4 we further sought to characterize the use of
subunit vaccines targeting the iron acquisition systems of P. aeruginosa, using peptide
and protein antigen formulations. While immunogenic, we identified that the formulations
we tested were not sufficiently protective from acute P. aeruginosa infection. Finally,
chapter 5 discusses implications of these findings on future formulations of vaccines and
immunotherapeutics against P. aeruginosa. The works described here enrich the
knowledge within the fields of Bordetella and Pseudomonas vaccinology and provide
additional perspective that will further the development of preventatives and therapeutics
for these pathogens.
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Chapter 2. Innate and adaptive
immune responses against
Bordetella pertussis and
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2.1

Abstract

Whole cell vaccines are frequently the first generation of vaccines tested for pathogens
and can inform the design of subsequent acellular or subunit vaccines. For respiratory
pathogens, administration of vaccines at the mucosa can facilitate the generation of a
localized mucosal immune response. Here, we examined the innate and vaccine-induced
immune responses to infection by two respiratory pathogens: Bordetella pertussis and
Pseudomonas aeruginosa. In a model of intranasal administration of whole cell vaccines
(WCVs) with the adjuvant curdlan, we examined local and systemic immune responses
following infection. These studies showed that intranasal vaccination with a WCV led to
a reduction of the bacterial burden in the airways of its respective pathogen. However,
there were unique changes in the cytokines produced, cells recruited, and inflammation
at the site of infection. Both mucosal vaccinations induced antibodies that bind the target
pathogen, but linear regression and principal component analysis revealed that protection
from B. pertussis correlated in particular to a reduction in neutrophils in the lung and an
increase of TNF- in the lung supernatants. Protection from P. aeruginosa however
correlated to a reduction in lung weight, blood lymphocytes and eosinophils, and the
cytokines KC/GRO and IL-12 in the lung supernatants, and increased serum IgG and IgA
antibodies. These findings reveal valuable correlates of protection for mucosal
vaccination that can be used for further development of both B. pertussis and P.
aeruginosa vaccines.
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2.2

Introduction

Airway tissue, including nasal passages, throat, and lungs, are constantly exposed to
bacterial, viral, and fungal species in the air we breathe. As a result, respiratory infections
are one of the leading causes of death (170) and accounted for 1.3 million visits to the
emergency room, 250,000 hospitalizations, and 50,000 deaths in the United States in
2017 (171, 172). Respiratory infection can be highly contagious and spread easily within
susceptible populations. In immunocompromised individuals and patients with chronic
health concerns such as cancer, chronic obstructive pulmonary disease, bronchiectasis,
or cystic fibrosis (CF), the risk and severity of respiratory disease is even higher (173).
To combat these infections, medications such as antibiotics and antivirals can be used
for treatment, or vaccines can be used as preventatives. Over the last century, protection
conferred by vaccination against respiratory diseases such as diphtheria, pertussis, flu,
pneumonia, or polio has decreased the burden of both bacterial and viral respiratory
infections and saved innumerable lives (38). However, there are still pathogens for which
antibiotics are failing, and no vaccine is approved for clinical use.
Recently classified as an “ESKAPE” pathogen (174), Pseudomonas aeruginosa is Gramnegative bacterium causing difficult-to-treat infections. P. aeruginosa has a high intrinsic
level of antibiotic resistance and can survive in diverse environments and conditions
(175). This bacterium is a common causal agent of hospital- and community-acquired
pneumonia in individuals who are immunocompromised or have the genetic disease CF
(176, 177). The development of immunotherapies such as vaccines or monoclonal
antibody therapy for these patients would represent a step forward in the prevention and
treatment of P. aeruginosa infections and provide an answer where antibiotics are failing
(146). For example, the vast majority of patients affected by CF suffer from intermittent
P. aeruginosa infections during their childhood and become chronically colonized by the
time they reach adolescence or adulthood (178, 179). P. aeruginosa is associated with
chronic inflammation, tissue damage, and increase in morbidity and mortality in these
patients. Unfortunately, while extensive research has been conducted in the field of
vaccine development against P. aeruginosa, there is currently no vaccine available.
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Therefore, it is of utmost importance to these at-risk populations that means of prevention,
rather than treatment, be developed.
Sometimes considered crude, whole cell vaccines (WCV) are often highly efficacious for
prevention of infection by pathogens and are often the first generation of vaccines to be
developed when a pathogen emerges as a threat. WCVs are produced from cultured
bacteria or viruses, either killed, inactivated, or attenuated by treatments such as gamma
irradiation, heat, or chemicals (180–184). These preparations contain immunostimulatory
endotoxin and a wide array of antigens. An example of a successful WCV is one that
prevents whooping cough, which is caused by the bacterium Bordetella pertussis. B.
pertussis is a respiratory pathogen that colonizes primarily the upper-respiratory airways
and is thought to be transmitted by aerosolization through cough. While the innate
immune system is involved in the initial control of B. pertussis during infection, complete
clearance often depends on the development of an adaptive immune response to the
organism (34). Pertussis WCVs (denoted here as Bp-WCV) were originally developed in
the 1940s and used in the US and Europe for most of the second-half of the 20th century
before being replaced in the 1990s by less reactogenic acellular vaccines (185). These
acellular vaccines induce a Th2 response and are protective against pertussis, but the
protection they provide quickly declines over time. As a result, countries in which acellular
pertussis vaccines were implemented are seeing a recrudescence in the number of cases
since their introduction (186). In contrast to acellular vaccines, the protection provided by
Bp-WCV lasts longer and is associated with a Th1 or Th17 response (34, 187, 188).
Numerous studies in the field have provided evidence that experimental pertussis
vaccines that emulate the response triggered by Bp-WCV can provide better protection
than currently approved acellular pertussis vaccines (189, 190).
The objective of our laboratory is to develop novel vaccines against the two respiratory
pathogens P. aeruginosa and B. pertussis. While the majority of vaccines approved for
human use are administered intramuscularly, we and others propose that administration
routes that mimic the natural route of infection lead to a localized and protective immune
response (27, 28). In this work, we studied the immune correlates of protection of whole
cell vaccines administered intranasally in a murine model of acute infection of B. pertussis
or P. aeruginosa. We characterized the adaptive immune response triggered by these
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vaccines and identified immunological signatures and correlates of protection associated
with whole cell vaccination.
2.3

Materials and Methods

2.3.1 Bacterial strains and growth
P. aeruginosa strain PAO1 was kindly provided by Dr. Michael L. Vasil (University of
Colorado). The PAO1 strain was grown on Pseudomonas Isolation Agar (PIA, Becton
Dickinson) at 36°C overnight. Bacteria were then swabbed off the plate and resuspended
in phosphate buffered saline (PBS). The bacterial culture in PBS was centrifuged for 10
min at 1,800 g and diluted with fresh PBS to OD600=0.75 (equivalent of 3x109 Colony
Forming Units (CFU)/ml) to be used for challenge unless otherwise specified.
B. pertussis strain UT25 (UT25Sm1) was kindly provided by Dr. Sandra Armstrong
(University of Minnesota). B. pertussis was grown first on Bordet-Gengou (BG) agar
(Remel) (35) supplemented with 15% defibrinated sheep blood (Hemostat Laboratories)
for 2 days at 36°C. Bacteria were then swabbed off the plate, resuspended in Stainer
Scholte medium (SSM) (191) and incubated at 36°C under constant shaking until
reaching OD600 = 0.6. Bacteria were then diluted to OD600 = 0.3 in SSM (equivalent to 109
CFU/ml) before being used for challenge.
2.3.2 Vaccine preparation
The bacteria present in the whole cell P. aeruginosa vaccine (Pa-WCV) were grown as
described above. This suspension was then heat-inactivated by treating the cells for 1h
at 60°C. Pa-WCV vaccine was prepared in 20 µl suspension containing 109 CFU/ml heatkilled P. aeruginosa PAO1 and 100µg of curdlan (Invivogen) in PBS.
The World Health Organization (WHO) standard whole cell B. pertussis vaccine (BpWCV) was acquired from the National Institute for Biomedical Standards and Control
(NIBSC). This vaccine was diluted to 1/12th of a human dose and supplemented with 100
µg of curdlan in PBS in a final volume of 20 µl before being administered to mice as BpWCV.
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2.3.3 Vaccination with B. pertussis and P. aeruginosa whole cell vaccines and
challenge
In all experimental groups, 6 weeks old outbred female CD1 mice (Charles River,
Frederick, MD, USA) were used. Mice were anesthetized by intraperitoneal injection (IP)
of 0.2 ml of ketamine (7.7 mg/ml) and xylazine (0.77 mg/ml) in 0.9% NaCl. Mice were
immunized intranasally with adjuvant only (100µg of curdlan in PBS), Bp-WCV, or PaWCV at day 0 followed by a booster of the same vaccine at day 21. A total of 34 days
after the first vaccination, mice were challenged with either live P. aeruginosa or B.
pertussis as described above in 20 µl of sterile PBS. The mice were euthanized at day 1
or 7 days post-infection by IP injection of 390 mg euthasol/kg in 0.9% NaCl. Immediately
following euthanasia, one day post-challenge, body temperature was measured by a noninvasive infrared thermometer on the abdominal region (192, 193). The lung and spleen
of each mouse were aseptically removed and weighed prior to processing, as described
below.
2.3.4 Detection of bacterial load
To determine bacterial loads in the airways post-euthanasia, nasal washes (NW) were
collected by flushing the nasal cavity with 1 ml sterile PBS. Lung samples were
homogenized with a 7 mL Dounce homogenizer (VWR, Corning Pyrex Pestle) in 1 ml
PBS. The lung samples and NW of each mouse were serially diluted and plated on PIA
plates if infected with P. aeruginosa, or BG agar if infected with B. pertussis, to determine
viable bacterial burden.
2.3.5 Histology
To perform histology, the lung from vaccinated and 1-day post-challenge mice were
cannulated and 1 ml of 4% weight/volume (w/v) paraformaldehyde (Thermo Fisher
Scientific, MA, USA) was injected to the lungs. Samples were then fixed for 48 h in 10
volumes of 4% w/v paraformaldehyde. Hematoxylin and eosin staining (H&E) was
performed by the West Virginia University Pathology Laboratory for Translational
Medicine. Slides were imaged at 20X and 100X magnification on EVOS XL Cell Imaging
System (Thermo Fisher Scientific, MA, USA).
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2.3.6 Hematology
Hematological analysis was performed using a Hemavet 950FS Veterinary Multi-Species
Hematology System (Drew Scientific FL, USA). The equipment was calibrated before
each experiment using mouse blood standards (Drew Scientific, FL, USA). Blood samples
isolated via cardiac puncture were placed in Microtainer blood collection tubes coated
with K2EDTA (Becton, Dickinson and Company, NJ, USA), shaken, and kept at 4°C until
analysis. Total white blood cells, neutrophils, lymphocytes, and monocytes were
quantified using the Hemavet 950 FS.
2.3.7 Flow cytometry analysis
After harvesting the organs at day 1 post-challenge, the lungs were homogenized as
described above. The homogenized samples were strained for separation through a 100
µm cell strainer and centrifuged at 1,000 x g for 5 min. The cell pellets were resuspended
in 1 ml of red blood cell lysis buffer BD Pharm Lyse (BD Biosciences, NJ, USA) and
incubated at 37°C for 2 min. After lysing red blood cells, the samples were centrifuged
and resuspended in PBS with 1% fetal bovine serum (FBS) and incubated for 15 min on
ice. Cells were incubated with the cocktail of fluorescently labeled antibodies
(Supplementary Table S1) for 1 hour at 4°C in the dark. The samples were then pelleted,
resuspended in 500 µl of PBS, and processed on the BD LSR Fortessa in the West
Virginia University Flow Cytometry & Single Cell Core Facility. The analysis was
performed using FlowJo version 10.3 (FlowJo, Becton, Dickinson and Company, NJ,
USA).
Seven days post-challenge, the splenocytes were Dounce homogenized and strained
with 100 µm cell strainer. The strained splenocytes were stained with specific cell surface
receptor and intracellular transcription factor markers (Supplementary Table S2). The cell
surface staining was performed as described above. Then the surface-stained cells were
centrifuged at 1,000 x g for 5 min and resuspend in PBS. We used BD Pharmingen™
transcription factor buffer and protocol for intracellular staining. Briefly, the cells were fixed
& permeabilized with 1 ml of 1X Fix/Perm buffer for 50 min at 4°C. The cells were washed
using 1 ml of 1X Perm/Wash buffer. After the wash, splenocytes were stained for
intracellular staining for 50 min at 4°C in the dark. The splenocytes were then pelleted,
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washed, and resuspended in 500 µl PBS. The flow cytometry analyses were performed
as described above.
2.3.8 Cytokine Analysis
Cytokine analysis performed on the lung homogenate supernatant, collected following
centrifugation of lung tissue homogenate at 14,000 x g for 4 min. The supernatants were
assayed at a dilution of 1:5 and 1:300 to detect the presence of cytokines using the Meso
Scale Discovery’s V-Plex Plus Pro-Inflammatory Panel 1 mouse multiplex assay kit; IFN, IL-1, IL-2, IL-4, IL-5, IL-6, KC-GRO, IL-10, IL-2p70, and TNF- were detected. The IL17 levels were measured by using Meso Scale Discovery’s mouse IL-17 Ultra-Sensitive
kit (Meso Scale Diagnostics, MD, USA). Results were analyzed following the
manufacturers guidelines.
Serology
Serology was performed using enzyme linked immunosorbent assay (ELISA) to
determine pathogen-specific antibodies in blood serum and nasal wash in vaccinated
mice. Blood isolated via cardiac puncture at 1-day post-challenge was centrifuged at
14,000 x g for 2 min and the supernatant serum was saved. Pierce high-binding 96-well
plates were coated with 50 µl either P. aeruginosa (2x107 CFU/well) or B. pertussis (2x107
CFU/well) overnight at 4°C, then washed three times with 200 µl of PBS-Tween 20 (PBST). Nasal wash was collected as described above. Following coating, plates were blocked
and incubated at 4°C overnight and then washed three times with PBS-T. P. aeruginosa
coated plates were blocked using with 200 µl of 2% v/v Bovine Serum Albumin (BSA) in
PBS and B. pertussis coated plates were blocked with 5% w/v milk in PBS. Serum
samples were loaded at a dilution of 1:50 in blocking buffer and then serially diluted. Nasal
wash was loaded without dilution. The serum or nasal wash-coated plates were incubated
2 h at 37°C, washed four times with PBS-T, then detected with 100 µl 1:2,000 anti-IgG, IgM, or -IgA (Southern Biotech AL, USA) secondary antibodies conjugated to alkaline
phosphatase. After one-hour incubation at 37°C, each well was washed five times with
PBS-T and loaded with 100 µl Pierce p-Nitrophenyl Phosphate (PNPP) solution (Thermo
Fisher Scientific, MA, USA), developed in the dark at room temperature for 30 min, and
the optical density at 405 nm was determined using a SpectraMax® i3 plate reader
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(Molecular Devices, CA, USA). Titers were determined by selecting the highest dilution
at which the absorbance was twice as high as the absorbance of the negative control.
The limit of detection for serum titers were 1:50. Values below the limit of detection were
represented with a value of one.
2.3.9 Statistics
Statistical analyses were done by using GraphPad Prism version 7 (GraphPad). The
group comparisons were analyzed by one-way ANOVA (analysis of variance) with
Tukey’s multiple-comparison test unless otherwise stated. Unpaired Student’s t-test was
used for comparisons of two samples. For cytokine analysis, multiple comparison analysis
was done by using Kruskal Wallis test with the Dunn’s multiple comparison test. For linear
regression and principal component analysis (PCA) of correlates of protection, only
biological replicates for which all data points were available were included in analysis.
Heatmap was created using Heatmapper web tool (194). PCA was performed using the
ClustVis web tool, and all data was normalized using a ln(x+1) transformation (195).
2.3.10 Animal Care and Use
All the mice experiments were approved by West Virginia University Institutional Animal
Care and Use Committees (WVU-ACUC protocols 14-1211 and 1606003173) and done
in accordance of National Institutes of Health Guide for the care and use of laboratory
animals.
2.4

Results

2.4.1 Whole cell intranasal vaccination against B. pertussis and P. aeruginosa
reduces bacterial colonization following challenge
The design of efficacious vaccines against bacterial pathogens requires a thorough
understanding of both innate and adaptive immune responses to these pathogens. In this
work, we studied the immune correlates of protection of WCVs administered intranasally
in a murine model of acute infection of B. pertussis and P. aeruginosa. Vaccines were
formulated with the adjuvant curdlan to induce a Th17 response (20, 25, 26, 141) as this
type of T cell response has been considered desirable within the field for both pathogens
(26, 94, 196, 197). Following intranasal vaccination and boost with WCV or adjuvant only,
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Figure 4. Intranasal administration of whole cell vaccination against P. aeruginosa or
B. pertussis reduces bacterial burden in lung and nasal wash following challenge with
each pathogen, respectively. A. Sixteen hours post challenge, nasal wash (A) and lung
(B) bacterial burden in euthanized mice groups. Each dot represents an individual
mouse, and the error bars represent the standard error of the mean. (n=6-10 per group)
The asterisks and bars refer to statistical significance determined by ANOVA with
Multiple Comparisons: **p ≤ 0.01; ****p ≤ 0.001. C & D. Correlation of number of
bacteria in nasal wash to number of bacteria in lung, per each type of infection. Color
filled points indicate adjuvant vaccinated animals, white filled points indicate animals
which had received whole cell vaccination. The R2 and p values were calculated using
linear regression analysis.
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mice were challenged with live bacteria, and the immune response to infection was
assessed one day post-challenge. We observed that mice vaccinated intranasally with
WCVs had reduced bacterial burden in the upper and lower respiratory tracts when
challenged with either P. aeruginosa and B. pertussis, compared to their adjuvant-onlyvaccinated counterparts (Figure 4A and B). We also observed that the bacterial burden
in the upper airway (nares) correlated with the burden in the lower respiratory tract for
both whole cell-immunized and adjuvant-only immunized animals (Figure 4C and D).
Together, these data highlight that whole cell vaccination effectively reduced bacterial
burden in both models.
Following challenge, we observed that infection with P. aeruginosa was associated with
a decrease in body temperature within the first 16 h of infection (Figure 5). While whole
cell vaccination resulted in a reduction of the bacterial burden in the airway, a significant
reduction in body temperature was still observed in response to challenge with P.
aeruginosa (Figure 5). Decreases in body temperature are often associated with an acute
response to lipopolysaccharide (LPS)(193). This hypothermic response was not observed
in the case of vaccination and infection with B. pertussis (Figure 5), whose outer
membrane contains lipooligosaccharide (LOS), rather than LPS.

Figure 5. Challenge with P. aeruginosa, but not B. pertussis reduces body temperature
of challenged animals. Body temperatures were measured using infrared thermometer
aimed at the abdominal region of the animal. (n=3-10) The asterisks and bars refer to
statistical

significance

determined

by

****p ≤ 0.001.
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ANOVA

with

multiple

comparisons:

2.4.2 Innate immune response in the lung following vaccination and challenge.
After observing that P. aeruginosa and B. pertussis whole cell vaccination lead to a
decrease in viable bacteria in the airway following challenge, we sought to determine if
this protection is associated with a decrease in tissue inflammation. P. aeruginosa
respiratory infections lead to immune cell and fluid influx in the lung (138). When we
measured the wet weight of the lung post-challenge, we observed that in the case of P.
aeruginosa infection in adjuvant-only vaccinated mice (NVC), the lung weight nearly
doubled when compared to non-vaccinated non-challenged (NVNC) mice (Figure 6A).
This severe increase in lung weight was significantly reduced in Pa-WCV immunized,
challenged mice (Figure 6A). In comparison, B. pertussis infection in adjuvant or Bp-WCV
vaccinated mice did not cause a significant increase in lung weight (Figure 6A).
These observations led us to hypothesize that P. aeruginosa and B. pertussis challenge
each lead to the recruitment of different immune cell populations to the lung. To test this
hypothesis, lung from vaccinated mice challenged with P. aeruginosa or B. pertussis were
extracted one day post-infection, fixed, stained with H&E, and sectioned for histological
analysis. In the case of P. aeruginosa infections in NVC mice, a large number of
polymorphonuclear cells were observed in the bronchi and as multiple foci in the alveoli
(Figure 6B). P. aeruginosa challenged mice that had received Pa-WCV showed a reduced
presence of these cells in the alveoli but not in the bronchi. A different pattern was
observed in the B. pertussis challenged mice: polymorphonuclear cells were observed to
a much lesser extent and were diffusely located throughout the lung parenchyma in the
B. pertussis NVC and Bp-WCV mice. Unlike our observations during P. aeruginosa
infections, the accumulation of these cells was not observed in the bronchi (data not
shown).
To identify the cell types involved in the acute response observed by histology, we
performed flow cytometry on the lung tissue. While no significant changes were observed
in the proportion of CD3e+ CD4+ T cells or CD3e+ CD8+ T cells present in the lungs
(data not shown), significant increases in myeloid cells (CD11b+ GR-1+) were observed
in the lung of mice challenged with P. aeruginosa (Figure 6C). This population included
primarily neutrophils (CD11b+ GR1high) and supports the histological observations from
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Figure 6B. Overall, the data presented here show that P. aeruginosa infections result in
the recruitment of myeloid cells, and in particular neutrophils, to the lung during the acute
phase of infection. This influx of cells occurs in parallel with the observed increase in lung
weight and obstruction of the airways. While vaccination with Pa-WCV is able to decrease
lung weight and recruitment of cells in the lung, it does not alter the overall composition
of innate immune cells recruited to the lung. These effects were not seen in mice
challenged with B. pertussis, in which little to no increase in lung weight and myeloid cell
recruitment was observed in the lung.

Figure 6. Signs of inflammation in the lung after-challenge. A. The lung masses of mice
groups at 16 h. post-challenge. B. H&E stained post-challenge lung sections imaged

at 20X and 100X magnification. C. Proportion of myeloid (CD11b+ GR-1+) and
neutrophil (CD11b+ GR-1high) cell populations in single cells of lung homogenates.
(n=10-12 per group) The asterisks represent a comparison of the indicated bar to
adjuvant-only non-challenge, and bars indicate statistical significance determined by
ANOVA: *p ≤ 0.05; **p≤ 0.01; ***p ≤ 0.001, ****p ≤ 0.001.
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2.4.3 Leukocytosis occurs during B. pertussis, but not P. aeruginosa, infection.
To fight infection, immune cells are mobilized from the bone marrow and circulate in the
blood before reaching the site of infection (198). This increase in circulating white blood
cells (WBC), is sometimes severe enough to be termed leukocytosis. Specifically during
B. pertussis infections, secreted pertussis toxin (PT) prevents innate immune cell
chemotaxis to infected tissue, effectively trapping cells in the circulatory system (199).
Leukocytosis can lead to the development of pulmonary hypertension and respiratory
failure, which are major causes of death for infants that contract the disease (42). To
examine the role of each pathogen and WCV on the mobilization of WBC after infection,
we performed hematology on mice one day post-challenge. First, we observed that B.
pertussis infection in non-vaccinated animals resulted in an overall increase in the number
of WBCs (Figure 7A), corroborating the hallmark leukocytosis that occurs in infected
humans (39). We observed that this change was due in large to increases in circulating
neutrophils (p = 0.0099) and lymphocyte populations in B. pertussis infected mice,
compared to non-challenged controls (Figure 7B). However, mice that had been
administered Bp-WCV prior to challenge did not have significant leukocytosis (Figure 7A),
nor significantly more neutrophils than non-challenged mice (Figure 7B). Leukocytosis is
not typically used as a marker for disease severity during P. aeruginosa respiratory
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Figure 7. The proportion of blood cell populations after-challenge. A. Total number of
white blood cells. B. Proportion of neutrophils, lymphocytes, and monocytes in total
white blood cells. (n=9-10 per group) The asterisks and bars indicate statistical
significance determined by ANOVA: **p ≤ 0.01.

infection. We did not observe changes in the total number of WBC in the adjuvant-only
vaccinated or the Pa-WCV P. aeruginosa infected mice (Figure 7A). There were,
however, other observable shifts in the types of WBC present. Challenged groups had a
higher proportion of circulating neutrophils, compared to adjuvant only vaccinated, and
this was exacerbated in animals which had received the Pa-WCV (p = 0.0055). The
opposite occurred in the B. pertussis groups: adjuvant vaccinated, and pertussis
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challenged mice had higher levels of neutrophils (p = 0.009) in their blood compared to
non-challenged. We also observed a reduction of leukocytosis in mice that received BpWCV, and the level of circulating WBC in these animals were similar to those of the nonchallenged controls (p = 0.88) (Figure 7B).
2.4.4 Vaccination plays a role in modulating the cytokine response to B. pertussis
but not P. aeruginosa infection.
The mobilization and recruitment of immune cells during infection is orchestrated by
changes in the levels of various signaling molecules such as cytokines and chemokines
(198). To gain insights into the differences in signaling underlying the recruitment of
myeloid cells in the lung observed and described above, we performed cytokine analysis
of the lung supernatant fluid one day post-infection using MSD multiplex assays
(Supplementary Table S3). The levels of these cytokines were then summarized and
represented as log fold changes relative to adjuvant-only vaccinated non-challenged mice
in Figure 8A. Overall, we observed that P. aeruginosa infection, regardless of vaccination
status, induced a relative increase in pro-inflammatory cytokines in the lung supernatant,
when compared to the non-challenged control. P. aeruginosa infection in adjuvant-only
vaccinated animals led to significant increases in IL-6, IL-1β, KC-GRO, and IL-12p70
relative to the non-challenged control (Figure 8F, G, N, P). IL-1β and IL-12p70 were
further increased in the Pa-WCV group, which suggests a Th1 type immune response is
induced as a result of these infections. Interestingly, we observed a significant reduction
in IL-6 and KC-GRO levels in the Pa-WCV compared to the adjuvant vaccinated group
(Figure 8F, N).
When examining cytokine changes during B. pertussis infection, we observed that the
overall changes were less pronounced than those observed in the P. aeruginosa
challenged groups. Rather than inducing a cytokine storm-like response, B. pertussis
infection, with or without immunization, caused a more specialized response. B. pertussis
infection in non-vaccinated mice induced modest but non-significant increases in IFN-γ,
IL-6, and IL-1β compared to non-challenged mice (Supplementary Table S2A-K).
However, in mice which had received Bp-WCV, we observed significant increases in IL17, IL-6, IL-1β, IL-5, IL-12p70, and TNF-α in the Bp-WCV group compared to non-
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challenged mice. A similar increase in IL-6 expression was observed in both adjuvantonly, and Bp-WCV vaccinated and challenged mice, suggesting that IL-6 production is
mainly triggered by challenge with B. pertussis, consistent with previous findings (200).
In addition, levels of TNF-α (p <0.01) in the Bp-WCV group were the only ones
significantly increased compared to the adjuvant-vaccinated and challenged group,
indicating that vaccination helps decrease the production of pro-inflammatory cytokines
upon challenge. Overall, the data obtained indicate that both pathogens trigger very
distinct cytokine responses upon infection with the B. pertussis challenge associated with
a Th1/17 response while P. aeruginosa triggers a cytokine storm. In addition, only the BpWCV, and not the Pa-WCV seemed to alleviate the pro-inflammatory cytokine response
associated with challenge.

Figure 8. Cytokine and T cell response to infection following whole cell or adjuvant only
vaccination. A. Heatmap showing the log (fold change) of cytokines in each mice group
compared to NVNC. Color represents an increase (dark green) or decrease (light

green). The asterisks indicate statistical significance determined by ANOVA: *p ≤ 0.05.
B-Q. Cytokines measured by multiplex assay. Asterisks over bars indicate comparison
to NVNC. LD indicates limit of detection. Bars indicate other comparisons, as
determined using ANOVA: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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2.4.5 Whole cell vaccination increases CD4+ Th17+ cells in spleen one week post
infection
In addition to the recruitment of immune cells to the site of infection, cytokines play a
major role in the stimulation of the T cell response in secondary lymphoid organs, such
as the spleen. To characterize the type of T cell response triggered by vaccination and
challenge against each of these pathogens, we performed flow cytometry on the
splenocytes, isolated 7 days post challenge. We did not observe changes in the total
numbers of T cells or subpopulations of CD4+ or CD8+ T cells in any of the groups (Figure
9A). However, significant increases in the proportion of CD4+ Th17+ cells were observed
in both the Pa-WCV and Bp-WCV groups compared to the adjuvant vaccinated, nonchallenged group (Figure 9B). This data corroborates the increase in IL-17 observed one
day post-infection and supports the importance of Th17 responses to these pathogens
following vaccination.

Figure 9. Whole cell vaccination leads to increase in Th17 cell populations within splenic
T cells. A. The frequency of CD4+ (CD3e+CD4+) or CD8+ (CD3e+CD4+) T cells in
splenocytes at day 7 post-infection (n=5-9 per group). B. The proportion of Th17 cells

(CD3e+CD4+RorγT+) within the CD4+ T cell population. The asterisks indicate
statistical significance determined by ANOVA: *p ≤ 0.05.
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2.4.6 Correlates of protection for B. pertussis and P. aeruginosa, using intranasal
whole cell vaccination as protective model.
Taken together, these data illustrate the striking differences between infection and
vaccine-induced protection against the respiratory pathogens B. pertussis and P.
aeruginosa. Infection by either of these pathogens without prior vaccination led to severe
disease. Vaccination was associated with a significant decrease in bacterial burden in the
airway for either pathogen and their respective vaccine, but the immune components
correlated with this protection were unique. Typically, serum antibody titers are used as
a correlate of protection in human studies (9). In order to examine the immunoglobulins
produced following vaccination and challenge, ELISA were performed to detect whole
bacteria specific antibodies in the blood serum. In both Pa-WCV and Bp-WCV groups,
we detected significant production of bacteria-specific IgG and IgA in the serum against
the respective pathogens (Figure 10). These findings support that intranasal
immunization can induce systemic immune responses to their respective pathogens.

Figure

10.

Vaccination

induces

pathogen specific antibody production.
A. Pa-WCV and (B) Bp-WCV serum IgG
and IgA titers. (n=5-12 per group) The
asterisks indicate statistical significance
determined
***p ≤ 0.001.
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by

ANOVA:

*p ≤ 0.05,

To get a bigger picture of the immunological factors correlated with the reduction of
bacterial burden in the airway, we performed linear regression analyses of the factors
described in Figures 2-7, and correlated data by biological replicate to the bacterial
burden in the lung (Figure 11A). The factors significantly correlated with protection from
P. aeruginosa infection were decreased lung weight, increased blood neutrophils,
decreased blood lymphocytes and eosinophils, and increased serum IgG and IgA (Figure
10). Nearly all the cytokines measured had positive correlation slopes, highlighting the
cytokine storm observed in P. aeruginosa infected animals, regardless of whether or not
they had received immunization. Mice protected from P. aeruginosa infection produced
P. aeruginosa-binding IgG and IgA, suggesting that the B cell response plays an
important role in fighting P. aeruginosa acute pneumonia infection. Looking into B.
pertussis correlates of protection, we observed that protected animals had a decrease in
the lung neutrophils and an increase in TNF-α (Figure 11A). Notably, protection from P.
aeruginosa was correlated with a trending decrease in most cytokines, but protective from
B. pertussis infection was correlated with trends of increases in cytokines. Finally, using
a principal component analysis, we compared each of these groups using all the immune
factors shown in Figure 11A, to examine overall variance between vaccinated groups
(Figure 11B). This analysis indicates that mice within each group formed a distinct cluster.
The healthy, non-vaccinated, non-challenged mice formed a cluster distinct from any
challenged group. Upon challenge with either P. aeruginosa or B. pertussis, the clusters
shifted and separated from the healthy animal group. However, they did not shift in the
same direction, indicating that their differences are pathogen specific. With prior whole
cell vaccination, the shift away from the NVNC group was diminished, but not totally
abrogated. Taken together, the PCA shows that the impacts of infection are pathogen
specific, as expected, and that whole cell vaccination can change the overall profile of the
response to infection.
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Figure 11. Measurement of correlates of protection. A. Correlation of bacterial burden
with measured immune components after challenge with B. pertussis or P. aeruginosa
(n=4 per group). The R2 and p values were calculated using linear regression analysis.
A higher absolute value of R2 indicates that the factor was strongly correlated with the
bacterial burden. Positive slope (pink) indicates increase in that factor was associated
with higher bacterial loads, whereas a negative slope (green) shows that the increase
in that factor was associated with reduced bacterial burden. B. Principal component
analysis of measured immune components, with experimental groups shows by color.
Purple is non-vaccinated non-challenged, blue is non-vaccinated, B. pertussis
challenged, red is Bp-WCV, green is non-vaccinated, P. aeruginosa challenged, and
orange is Pa-WCV.
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2.5

Discussion

One of the best ways to prevent life-threatening or antibiotic resistant respiratory
infections is to vaccinate. Interestingly, only a few vaccines exist for respiratory bacterial
pathogens, including B. pertussis, Mycobacterium tuberculosis, and Streptococcus
pneumoniae. Therefore, there remains a significant need to develop vaccines for other
clinically relevant bacteria (50, 201). A frequent first choice for vaccine development is
whole cell vaccines (WCV), containing killed or attenuated versions of the pathogen.
These introduce to the host’s immune system hundreds or thousands of the pathogen’s
antigens. WCVs sometimes have strong reactogenicity that may cause undesired side
effects following administration (48). In addition, batch-to-batch and manufacturer
differences in the methods used in the laboratory to grow the bacteria used for the
formulation of WVC can strongly affect vaccine efficacy, which was one of the issues with
Bp-WCV (202). Further, laboratory-adapted strains are often used and may not induce
sufficient protection against the more diverse clinical strains (203, 204). However, WCVs
can be ideal tools for characterizing effective immune responses that can be used to
benchmark acellular or subunit vaccines. Here, a comparison of the standard version of
a vaccine approved for use in humans to prevent pertussis (NIBSC Standard; Bp-WCV)
to a lab-produced WCV for P. aeruginosa allows us to characterize the immune
responses to each broadly. These studies identified some of the ways each vaccine alters
the response to acute infection by their respective pathogens.
While the protection elicited by Bp-WCV has been well characterized in the field, only few
studies have focused on mucosal administration of pertussis vaccines (26, 196). In
addition, this work highlights some of the differences between the immune responses to
Bp-WCV and Pa-WCV. In the model used in this study, both intranasally administered
vaccines were capable of inducing a systemic, protective response to their respective
pathogen. Following vaccination using Pa-WCV formulated with heat killed P. aeruginosa
and the adjuvant curdlan, mice had reduced bacterial burden in their nasal wash and
lung, compared to mice vaccinated only with the adjuvant curdlan. Similarly, when mice
were vaccinated with the Bp-WCV containing the adjuvant curdlan, they had decreased
bacterial burden in both their nasal wash and lung, compared to when they are vaccinated
with adjuvant only. In both infection models, we identified a significant correlation between
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bacterial burden in the nasal wash to the burden in the lung. Against infection with either
pathogen, whole cell vaccination was sufficient to induce a protective immune response
and increased bacterial clearance. However, when we delved further into the nuances of
the immunological response in each vaccination group, we observed key pathological
differences, highlighting that whole cell vaccines are not the final answer for all
pathogens.
One of the hallmarks of respiratory infection is the induction of inflammation and cell
recruitment to the lung, causing severe damage to the tissue, altering lung function, and
in severe cases, leading to pneumonia (171, 172). Concurrent with these findings in
humans, we observed that infection by P. aeruginosa triggered a pneumonia-like
response, including an increase in the weight of the lung following infection and
recruitment of immune cells to the tissue. This observation may be caused by the actions
of LPS, endotoxin A, and phospholipase C (136). Using histological and flow cytometric
analysis of the lung, we identified the key contributors to the inflammation in the lung
following P. aeruginosa challenge as myeloid cells and neutrophils. While mice that were
vaccinated with the Pa-WCV had a reduction in lung weight compared to the adjuvant
vaccinated, and P. aeruginosa challenged mice, the percentage of myeloid cells, and in
particular neutrophils, remained elevated. Therefore, we hypothesize that the increase in
lung weight following P. aeruginosa challenge is more likely a result of pulmonary edema,
which is in line with observations of pneumonia in murine models and could be more
thoroughly analyzed in future studies (205, 206).
Within the field of P. aeruginosa vaccine research, it has been difficult to identify the
required immune components for a protective immune response (146). It is hypothesized
that a delicate balance between neutrophils, macrophages, and dendritic cells is vital for
successful clearance of the pathogen from infected tissue (146, 207). Neutrophils in
particular have been recognized within the field as important players for both the
clearance of P. aeruginosa, and also for lung-pathologies associated with exacerbated
responses (208–211). In various animal models, P. aeruginosa infection in neutropenic
animals is lethal (211–213). Neutrophils can kill pathogens by phagocytosis and secretion
of NETs that trap pathogens. Neutrophils have been detected at elevated levels in
chronically infected CF patients, but evidence showing that this response is beneficial to
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the patient is debated (214–216). In fact, neutrophils may lose the ability to kill the
bacteria, and instead induce gene expression changes in the bacteria that help them
establish chronic infection (214, 216). Macrophages, particularly alveolar macrophages,
which are the first line of defense in the lower airway, have also been shown to fight P.
aeruginosa respiratory infections (212). Likely, it is a combination of each of these cell
types responsible for preventing and fighting P. aeruginosa infections in this model.
Contrary to what we observed in the P. aeruginosa groups, infection using B. pertussis in
naïve or vaccinated mice did not result in an increase in the weight of the animal’s lung.
This observation was in line with a lack of infiltration of myeloid cells or neutrophils in the
lung observed by both flow cytometry and histology. The lack of neutrophil infiltration in
the lung in B. pertussis infected animals is likely associated with the presence of
leukocytosis in these animals. Leukocytosis, or accumulation of leukocytes in the blood
to an abnormally high level, is one of the hallmark characteristics of a B. pertussis
infection (217). Leukocytosis is present in most pertussis cases in humans and is one of
the main contributors to infant death due to pertussis (218). The pathogen’s namesake
toxin, PT, is the agent responsible for this response. The neutralization of PT is essential
for protection against B. pertussis. For this reason, PT is one of the primary components
(and sometimes the sole component) of acellular pertussis vaccines. To characterize
leukocytosis in our murine model, we quantified total white blood cells, neutrophils,
lymphocytes, and monocytes in the blood of mice 16 h post challenge, utilizing complete
blood cell analysis. As expected, leukocytosis, was detected only in naïve pertussis
challenged mice, compared to naïve non-challenged animals. Leukocytosis in response
to B. pertussis challenge was reduced in Bp-WCV vaccinated mice compared to adjuvantvaccinated mice. Since the levels of anti-PT antibodies produced in response to Bp-WCV
vaccination are typically low (26, 187), the decrease in leukocytosis is likely associated
with better control of bacterial burden and infection severity.
The chemokines and cytokines secreted by the antigen presenting cells, other first
responders such as neutrophils, and the memory cells formed following vaccination can
interact to dictate the type of immune response that occurs rapidly following challenge.
To characterize this interplay, we used MSD multiplex assays to quantified cytokines in
the lung supernatant 16 h post challenge, and calculated fold changes relative to the
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levels detected in mice that were adjuvant vaccinated and not challenged. We observed
two very striking phenotypes. First, P. aeruginosa challenge induced increase of every
cytokine measured. This phenomenon, of overall increase in cytokines is known as
cytokine storm, and together with decreases in body temperature, can be related to LPS
toxicity during infection (193, 219). Cytokine storm frequently occurs with severe P.
aeruginosa challenge (219, 220). Interestingly, the Pa-WCV immunization reduced the
pro-inflammatory cytokines IL-6, IL-12, and KC-GRO, compared to the levels of these
cytokines observed in non-vaccinated and challenged mice. IL-6 is produced by
phagocytes following activation, which helps to increase neutrophil antimicrobial
functions, and push differentiation of Th17 cells. In the context of P. aeruginosa, where
the toxin ExoA can induce IL-6 expression, this cytokine has a role in effective recruitment
of neutrophils to the cornea during P. aeruginosa infection (221, 222). IL-12 is required
for Th1 differentiation and is known to increase production of IFN-γ, and other cytokines
by phagocytic cells. Finally, KC-GRO, also known as CXCL1 or neutrophil-activating
protein 3 (NAP-3), is a chemokine that can be produced in response to IL-1 to recruit
neutrophils and other phagocytic cells following LPS and other PAMP exposures (223).
An increase in KC-GRO levels may result in the observed increase of neutrophils in the
lung tissue of infected animals. A significant decrease of these three cytokines in the lung
supernatant may indicate that, while there are still elevations of all cytokines at this early
time point, whole cell vaccination may eventually lead to the immune system being able
to resolve the inflammation and recruitment of neutrophils caused by infection.
B. pertussis challenge in non-vaccinated animals induced modest increases in some of
the cytokines measured, but we observed that vaccination led to the accentuated
expression of IL-1β, IL-5, TNF-α, IL-12, and IL-10. IFN-γ was elevated in both B. pertussis
infected groups and increased even further in the Bp-WCV. Pertussis toxin can stimulate
dendritic cells to produce IL-12, and NK and T cells to produce IFN-γ to push a Th1
response (224, 225). IFN-γ is required for the control of B. pertussis infections (226). Th1
cells play an essential role in the clearance of B. pertussis in the context of primary
infection or after immunization with Bp-WCV (227), and children who survive whooping
cough and become convalescent have primarily a Th1 response (228, 229). Interestingly,
we observed that IL-17 was detected in both of the B. pertussis challenged groups, which
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has been previously observed in mice during B. pertussis infection. This might be in part
driven by the pore-forming activity of ACT that promotes NLRP3 activation, pro-IL-1β
processing to mature IL-1β, and expression of IL-23 (230). IL-17 is important for
protection against B. pertussis and is often observed at later time points in naïve infected
mice (7-14 days post-challenge) (200, 231), and is more highly induced by the B.
pertussis whole cell vaccine than the acellular B. pertussis vaccine (34). Consistent with
the increase in IL-17 in lung supernatant, we observed an increase in splenic Th17 cells
in the Bp-WCV group compared to non-vaccinated and non-challenged mice. B. pertussis
has been shown to lead to the production and expansion of IL-17 producing pathogenspecific resident memory γδ T cells in the lung of B. pertussis infected mice (231). While
this localized adaptive response to infection is thought to be crucial for immunity to
subsequent re-infections, currently used Bp-WCVs are administered intramuscularly, and
few researchers have investigated the use of mucosal immunization against B. pertussis.
One notable difference between B. pertussis and P. aeruginosa is the type of endotoxin
produced by each bacterium. P. aeruginosa produces LPS, whereas B. pertussis
produces LOS, which contains Lipid A and the core domains, but lacks the O-antigen
component found in LPS. This loss results in overall decreased immunogenicity and
toxicity by LOS compared to LPS, and likely impacts the immunogenicity and
reactogenicity of each whole cell vaccine. The adjuvant-like role of endotoxin in vaccinemediated responses has been more deeply appreciated in recent years. Research
exploring the use of modified LOS or LPS components as adjuvants, including the
development of monophosphorylated lipid A (MPLA) as a TLR4 agonist, has open new
doors for the development of effective vaccines (232, 233). In future studies, this
difference could be further examined to determine the impact of unique endotoxins on the
efficacy of whole cell vaccines, as well as the use of these bacterial products as adjuvants
in subsequent acellular vaccines.
Recent works in both the Pseudomonas and Bordetella fields have demonstrated the
importance of inducing Th17 responses (141, 197). Here, the vaccines were formulated
with the Th17 skewing adjuvant curdlan and administered in a mucosal route. The
adjuvant curdlan is known to induce a Th17 type response (20, 26, 141). Intranasal
immunization triggers Th17-biased immune responses and is associated with IL-17 and
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IL-6 production (234). IL-17 production in the lung is also associated with the induction of
IgA, which we also observed during serological analysis (235). Put together, we
hypothesized that intranasal administration of a curdlan adjuvanted vaccine should
induce a strong Th17 and IL-17 response, which is consistent with what we observed for
both of the whole cell vaccines tested in this report. However, the strong activation of a
pro-inflammatory response may not be optimal in each of these infections. Having
observed that this combination resulted in response to Pa-WCV that was unable to
resolve the inflammation observed, the formulation of adjuvant and route of immunization
may need to be revisited in the future.
Our observation that mucosal immunization induced strong systemic antibody response
supports the use of this vaccination strategy in the future. IgG is a hallmark of vaccine
mediated protection and can have functions such as complement-mediated killing or
opsonization, and typically signals a systemic response to a vaccine or pathogen
exposure. This is important, given that these vaccines were administered intranasally,
which is considered a less immunostimulatory route for vaccine administration (28). In
addition to IgG, we observed the presence of circulating pathogen-specific IgA antibodies.
IgA antibodies are found in circulation and on mucosal surfaces and are thought to be
important for mucosal immune response as one of the first lines of defense against
respiratory pathogens such as P. aeruginosa and B. pertussis.
This study highlights that the immune response to respiratory infections varies widely
between bacterial pathogens, even when performed in the same infection model and with
the same vaccination parameters. In addition, this work gives evidence to support that
whole cell vaccination with different pathogens do not induce identical adaptive
responses, even when identical adjuvants and routes of immunization are used. We
demonstrated that mice administered the Bp-WCV were able to resolve many of the proinflammatory reactions to infection by B. pertussis, but that Pa-WCV immunized animals
did not as effectively resolve inflammation during P. aeruginosa infection. While both
vaccines increased the clearance of bacteria by one day post challenge, the symptoms
of illness associated to P. aeruginosa infection persisted regardless of Pa-WCV
administration. Overall, this study demonstrated many of the key differences in the
pathogenesis of B. pertussis and P. aeruginosa and how whole cell vaccination elicits
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protection for each against an acute respiratory challenge. These findings lay the
foundation for the identification of mechanistic correlates of protection for each pathogen,
which will be vital for the development of next generation vaccines.
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3.1

Abstract

Whole cell vaccines have been used for centuries to prevent bacterial infections.
Interestingly, some whole cell vaccines such as the one used for the prevention of
pertussis (Bp-WCV), have unique non-specific effects and can help protect against other
pathogens. In this work, we sought to determine the impact of Bp-WCV administration on
challenge with the Gram-negative opportunistic pathogen Pseudomonas aeruginosa in
mice. We determined that Bp-WCV can protect mice from acute P. aeruginosa respiratory
infection by decreasing bacterial burden in the airways to the similar levels than P.
aeruginosa whole cell vaccination (Pa-WCV). We observed by ELISA that Bp-WCV
induced production of cross-reactive antibodies that bind P. aeruginosa. We confirmed
these findings by immunoblotting and determined that antibodies elicited by Bp-WCV bind
two products in the bacterial lysate. Using immunoprecipitation, mass spectrometry, and
subsequent immunoblotting, we identified those cross-reactive antigens as OprF and
GroEL. We observed that the sequence of these two proteins is highly conserved in
clinical P. aeruginosa isolates, and that Bp-WCV cross-reactive antibodies also bind
broadly diverse clinical isolates. Altogether, these findings identify a novel antigenic
source for vaccination against P. aeruginosa, and provide additional evidence that B.
pertussis whole cell vaccination induces non-specific protection from other bacterial
species in mice.
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3.2

Introduction

Antibiotic-resistant bacterial infections represent a significant burden in the United States
and globally, accounting for more than 2.8 million infections and 35,000 deaths yearly in
the U.S. alone (63). As a result, the threat of antibiotic resistant infections continues to
drive the development of preventative measures, such as vaccines (63, 236, 237). Whole
cell vaccines are designed to train the immune system to mount a response against a
pathogen of interest. Antigens contained in the vaccines are processed, presented by
antigen-presenting cells, and trigger the activation of an adaptive immune response. This
pathogen-specific immune response can then be recalled during a potential exposure to
the live pathogen.
While the protection of whole cell vaccines is typically studied in the context of protection
from the pathogen contained in the formulation, nonspecific effects of whole cell vaccines
have also been observed (238–243). These nonspecific effects can be mediated by both
innate and adaptive immune systems in response to vaccination. In some instances,
vaccination can protect against other pathogens through the production of cross-reactive
antibodies that bind closely-related antigens in other organisms (239, 244, 245). For
example, some anti-flu antibodies can protect against heterologous strains of the virus,
and exposure to flaviviruses prevents subsequent infection by other flaviviruses (246,
247). Fungal Candida albicans Hyr1 protein can induce a protective response against
Acinetobacter baumanii surface proteins, via either active and passive immunization
(248). Another example is Herpesvirus latency, which is also able to induce protection
against the bacterial pathogens Listeria monocytogenes and Yersinia pestis (249).
In addition to protection mediated by cross-reactive antibodies, it is now well-established
that whole cell vaccines are able to induce trained innate immunity that leads to epigenetic
reprogramming of innate immune cells, including monocytes and macrophages, allowing
for a quicker response to exposure to a different pathogen (250–252). For example,
the Bacille Calmette-Guérin (BCG) vaccine for Mycobacterium tuberculosis used in
countries where TB is still prevalent, modulates the innate immune response and induces
protection against non-mycobacterium species and some types of cancers (250–253).
Similar effects have been observed with the MMR vaccine (254, 255).
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A growing body of evidence supports that whole cell pertussis vaccines (denoted here as
Bp-WCV) also provide non-specific protection against other pathogens. Bp-WCV protect
against Bordetella pertussis, the causative agent of whooping cough. In addition, it was
recently shown that co-administration of the commercially available Diphtheria, Tetanus,
and Pertussis (DTP) vaccine with BCG is associated with increased efficacy of the BCG
vaccine and improves overall outcomes for children (243, 256, 257). More recently, BpWCVs have also been used to adjuvant flu, peptide-based, and toxoid vaccines (239–
241). Furthermore, the live-attenuated B. pertussis vaccine BPZE1 currently in clinical
phase of development, is also known to induce a short-term cross-protective response
against S. pneumoniae (258).
Altogether, these data led us to investigate additional and potentially beneficial nonspecific effects of the Bp-WCV against the antibiotic-resistant bacterium Pseudomonas
aeruginosa. This pathogen is a major causative agent of antibiotic-resistant infections and
has no vaccine approved for human use. Our laboratory recently demonstrated using
mechanistic studies that the B-cell mediated immune response is essential for protection
during vaccination with a P. aeruginosa whole cell vaccine (Pa-WCV) (32). From this
work, we started evaluating novel methodologies to improve the B-cell mediated immune
response to P. aeruginosa vaccination to increase vaccine efficacy. We highlighted key
differences between vaccine-mediated protection provided by either Pa-WCV or Bp-WCV
(31), which led us to hypothesize that vaccination with Bp-WCV could potentially enhance
the immune response to P. aeruginosa, in a manner similar to BCG (243).
To test our hypothesis, we evaluated Pa-WCV and Bp-WCV alone and in combination in
a model of vaccination and P. aeruginosa pneumonia challenge. Through this work, we
discovered that Bp-WCV alone is sufficient for protection against P. aeruginosa challenge
and proceeded to identify the antigens involved in this nonspecific response.
3.3

Materials and Methods

3.3.1 Bacterial strains and growth
P. aeruginosa strain PAO1 was used for vaccine preparation and murine challenges. For
assays using transposon mutants, we utilized the University of Washington Transposon
Library of PAO1 transposon insertion mutants (259). To prepare a challenge dose of P.
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aeruginosa, PAO1 was grown on the Miller formulation of lysogeny agar (LA-Miller)
overnight at 36°C. A single colony was used to start 3 mL cultures, which were incubated

Table 1. Transposon mutant strains of P. aeruginosa used in study.
Gene ID

Strain

Pa ORF

Position in ORF

Transposon

oprF-1

PW4134

PA1777

432(1053)

ISlacz/hah

oprF-2

PW4135

PA1777

124(1053)

ISlacZ/hah

while shaking, overnight at 36°C. To prepare a culture in exponential phase, aliquots of
the overnight culture were diluted 1:100 in fresh LB, allowed to grow for approximate 4-5
hours, then centrifuged, resuspended in sterile 1X PBS, and diluted to an infectious dose
of 3-5 x 107 CFU/20 µL, using optical density (OD600). Dose was quantified using serial
dilution and plating on Pseudomonas isolation agar (PIA).
PAO1 transposon mutant and parental strains were struck on LA-Miller supplemented
with tetracycline (50 µg/mL) (Table 1). Clinical isolates of P. aeruginosa, described by
Burns et al. (74), were kindly provided by Dr. Robert Ernst (Table 2). Strains were grown
on PIA overnight at 37°C.

Table 2. Clinical isolate strains used, and their phenotypes, described by Burns et al.
(74). BAL=bronchioalveolar lavage, OP=oropharyngeal swab, M=mucoid, NM=nonmucoid

Strain ID

Source

Mucoid

Colony
Shape

Colony
Size

CEC34

BAL

M

Irregular

Large

Mint

> 1 cm

+

CEC38

OP

NM

Round

Small

Cucumber > 1 cm

+

CEC45

OP

NM

Irregular

Small

Cucumber Surface
swarming

+

CEC55

OP

M

Round

Large

Cucumber < 1 cm

+

CEC65

OP

M

Round

Large

Sea Spray < 1 cm

-/+

CEC76

OP

M

Round

Medium

Cucumber > 1 cm

+

CEC86

BAL

NM

Irregular

Small

Cucumber < 1 cm

+
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Color

Swimming

Rhamnolipid

3.3.2 Vaccine preparation
Pseudomonas aeruginosa whole cell vaccine (Pa-WCV) and Bordetella pertussis whole
cell vaccine (Bp-WCV) were prepared as described previously in Blackwood et al. (31).
Briefly, P. aeruginosa PAO1 Vasil was grown on Pseudomonas isolation agar (PIA)
overnight, swabbed from the Petri dish into sterile, endotoxin-free phosphate buffered
saline (PBS), diluted, and heat-killed by incubation for 1 hour at 60°C. For vaccination
against B. pertussis, we used the National Institute for Biological Standards and Control
(NIBSC) as whole cell vaccine, and Infanrix as acellular vaccine, each diluted to 1/50th of
the human dose. Vaccines were formulated to include 20 µL of the killed bacterial
suspension, and either 200 µg of the adjuvant curdlan or 62.5 µg of the adjuvant alum, in
a total volume of 40 µL if administered intranasally, 50 µL if administered intramuscularly
or intraperitoneally. Curdlan was prepared as described previously and mixed into the
vaccine immediately before administration (26, 31, 32, 196). Alum adjuvanted vaccines
were allowed to adsorb for 1 hour at room temperature, with rotation, and were thoroughly
mixed immediately prior to administration to animals.
3.3.3 Murine immunization and challenge models
To examine efficacy of the vaccines in an out-bred mouse model, groups of 6-week-old
CD-1 (Charles River) female mice were used. To examine efficacy in a more clinically
relevant model for cystic fibrosis, groups of transgenic β-ENaC mice were used, in
comparison to wild-type (WT) C57BL/6 littermates. For these studies, 13-15-week-old
female mice, age matched per group, were used. All animal care and use was in
compliance with the National Institutes of Health Guide for the Care and Use of Laboratory
animals. The animal protocols used in this study were approved by the West Virginia
University Institutional Animal Care and Use Committee (WVU-ACUC protocol
1606003173).
Vaccines, described above, were administered either intranasally under anesthesia, as
described previously (31), or intraperitoneally, and compared to adjuvant-only
vaccination. Vaccines were administered to mice on days 0 and 21. Thirty-four days post
initial vaccination, mice were anesthetized as described above, and infected intranasally
with 20 µL of bacterial culture containing 3-5 x 107 CFU PAO1. Approximately 14-16 hours
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post-infection, mice were euthanized by IP injection of 390 mg pentobarbital/kg (Patterson
Veterinary) in 0.9% NaCl. Following euthanasia, blood was collected via cardiac puncture.
Lung and spleen were aseptically removed and weighed prior to any further treatment or
analysis. Nasal lavage was collected by pushing 1 mL of sterile PBS through the nasal
cavity.
Bacteria were quantified in the lung and nasal wash. The nasal wash was serially diluted
and plated on PIA, then grown overnight at 36°C. The lung was homogenized using a
polytron PT 2500 E homogenizer, then similarly serially diluted, plated, and grown
overnight.
3.3.4 Serology
Antibody titers were quantified using an enzyme-linked immunosorbent assay (ELISA).
96-well microtiter plates were coated with 50 µL of PBS containing 2 x 10 7 CFU grown
overnight on PIA. Following coating, plates were washed thrice with PBS+0.05% Tween
20 (Fisher Scientific) (PBS-T), then blocked using 2% weight/volume (w/v) bovine serum
albumin (BSA) overnight at 4°C. Serum samples were prepared by diluting in 2% w/v BSA
at a dilution of 1:50, diluted serially down the plate to a maximum dilution of 1:819200,
and incubated overnight at 4°C. Following treatment with the serum, plates were washed
four times with PBS-T. Anti-IgG secondary antibody conjugated to alkaline phosphatase
(SouthernBiotech) was diluted 1:2,000 in blocking buffer and 100 µL were added to each
well, then incubated at 36°C for one hour. Plates were washed 5 times with PBS-T,
then incubated with Pierce p-Nitrophenyl Phosphate (PNPP) (Thermo Fisher Scientific)
for

30

minutes,

per

the

manufacturer’s

instructions.

OD405

was

quantified

using SpectraMax i3 (Molecular Devices LLC). Titer was quantified by calculating the
highest dilution at which the OD405 signal was double that of the blank, and any samples
for which no signal was detected was assigned a value of 1 (31, 196).
3.3.5 Whole Body Plethysmography
To examine the impact of infection, with or without prior vaccination, on the breathing and
respiratory function of animals, we studied WT and β-ENaC transgenic mice in a Buxco
Small Animal Whole Body Plethysmography (WBP) chamber (Data Sciences
International). Animals were acclimated to the chamber during a 20-minute session in the
59

week prior to the recorded WBP sessions. A baseline measurement of breathing was
recorded the day prior to infection, and then post-infection breathing was monitored
immediately prior to euthanasia, 15 hours post-infection. All WBP sessions included 5
minutes of acclimation, then data were recorded for 15 minutes. Data was compiled and
analyzed using FinePointe software, then exported to GraphPad Prism for statistical
analysis. Collected data include breaths per minute, enhanced pause, pause, EF50, tidal
volume of breath (TVb), time of inspiration (Ti), and time of expiration (Te). Linear
regression analysis was performed to identify which datasets correlated with bacterial
burden.
3.3.6 Immunoblotting
To further examine the binding of antibodies in the polyclonal serum, we performed
western blot analyses using serum from vaccinated or non-vaccinated groups against
bacterial lysates and purified proteins. Bacteria of interest were grown as described
above, swabbed into sterile PBS, lysed using sonication, and the protein concentration
quantified using bicinchoninic acid assay (BCA) (Thermo Fisher). Unless otherwise
designated, 10 µg of protein were added to Laemmli buffer (Bio-Rad) + 355 mM βmercaptoethanol, and boiled at 95°C for 5 minutes. Samples were loaded into Invitrogen
Novex WedgeWell 10% Tris-Glycine protein gel, and resolved by gel electrophoresis.
Proteins were then transferred using a wet-transfer method onto rehydrated PVDF
membranes (Bio-Rad), and the membranes were blocked overnight in 5% w/v skim milk
in PBS-T at 4°C. Next, membranes were treated with pooled murine serum samples, at
a concentration of 1:5000 in 1% w/v skim milk in PBS, for two hours at room temperature,
with orbital shaking. The membranes were washed 3 times with PBS-T then treated with
anti-IgG

secondary

antibody

conjugated

to

horseradish

peroxidase

(HRP)

(Immunoreagents) at a 1:5,000 concentration in 1% w/v skim milk in PBS, for 1 hour at
room temperature with orbital shaking. The membranes were washed again 4 times in
PBS-T and developed using SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Scientific). Chemiluminescence signal was detected using a Chemidoc Touch
Imaging System (Bio-Rad). For analysis, the chemiluminescence images were overlayed
onto colorimetric images of the ladder, visualized, and analyzed using Image Lab
software (Bio-Rad).
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3.3.7 Immunoprecipitation and mass spectrometry
P. aeruginosa PAO1 was grown as described above, and 750 µg of PAO1 culture lysate
was incubated overnight with pooled Bp-WCV serum. Immunoprecipitation was
performed using the Pierce MS-Compatible Magnetic IP Kit and Protein A/G beads, per
the

manufacturer’s

immunoprecipitation

instructions
products

(Thermo

were

Scientific).

analyzed

by

The

Liquid

resulting

purified

chromatography–mass

spectrometry in the WVU Mass Spectrometry CORE Facility, according to the protocol in
Shevchenko et al. (260). Data were acquired on a Thermo Q Extractive massspectrometer, and peptides identified were mapped using Proteome Discoverer software
version 2.3.0.523, using the SeQuestHT algorithm. The database used for mapping was
Pseudomonas aeruginosa PAO1 SwissProt TaxID=208964. Only peptides of high
confidence designation by SeQuestHT were considered.
3.3.8 Protein structure modeling
Proteins of interest were visualized in UCSF Chimera software (261). Protein structures
for P. aeruginosa OprF (PDB ID: 4RLC) and OmpA (PDB ID: 5U1H) were downloaded
from Protein Data Bank (PDB). Homology modelling of B. pertussis OmpA was performed
using SWISS-MODEL homology modeling server, and the highest homology protein was
selected for reference (PDB ID: 5U1H). Both GroEL structures depicted were modelled
similarly using SWISS-MODEL, and based on GroEL from Xanthomonas oryzae (PDB
ID: 6KFV). In comparing P. aeruginosa and X. oryzae protein sequences, there was a
78.05% sequence identity, and the model had a QMQE score of 0.80 and QMEAN of 0.15. Similarly, the B. pertussis GroEL had 75.19% identity with the X. oryzae protein
sequence, and the model had a QMQE score of 0.79 and QMEAN of -0.67. Structures
were visualized and overlaid using the MatchMaker structure analysis tool in UCSF
Chimera software (261).
3.4

Results

3.4.1 B. pertussis whole cell vaccine protects outbred CD-1 mice from acute P.
aeruginosa respiratory infection
It has been previously reported that B. pertussis whole cell vaccination can acts as an
adjuvant when formulated with other vaccines and protects against other bacterial
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pathogens (190, 239, 240, 243, 258). Our laboratory has a long-standing interest in
developing vaccines against both B. pertussis and P. aeruginosa. Here, we hypothesized
that Bp-WCV has adjuvant-like properties when administered in combination with PaWCV, and enhances protection against P. aeruginosa challenge. In previous studies, our
laboratory characterized the mechanisms of protection of mucosal administration of a
curdlan-adjuvanted inactivated whole cell vaccine (31, 32). Therefore, we first tested our
hypothesis in this well-characterized model, using intranasal vaccine administration. Mice
were vaccinated and boosted on days 0 and 21, and infected intranasally with P.
aeruginosa at day 35. One day post-infection, we euthanized animals and determined
bacterial burden in the respiratory tract. We observed that curdlan-only vaccinated mice
were heavily colonized in both the lung and nasal wash (Figure 12). In comparison to
curdlan-only vaccinated, both the Pa-WCV + curdlan and the combined Pa-WCV + BpWCV + curdlan vaccinated animals had a significant reduction of bacterial burden in the
lung (Figure 12A). However, combination of both vaccines did not provide additional
protection compared to Pa-WCV alone. Surprisingly, the animals which had received only
the Bp-WCV also showed a significant reduction in P. aeruginosa bacterial burden in the
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lung, indicating that vaccination with Bp-WCV alone is sufficient for protection against P.
aeruginosa (Figure 12).

Figure 12. Intranasal vaccination with P. aeruginosa and B. pertussis whole cell
vaccines adjuvanted with curdlan decreases bacterial burden in the respiratory tract
one day post infection. Sixteen hours post challenge, groups of mice were dissected
and the bacterial burden in the lung (A) and nasal wash (B) were quantified using serial
dilution. Each dot represents an individual mouse, and error bars represent standard
error of the mean. The asterisks represent statistical significance determined by
ANOVA with Multiple comparisons: * p ≤ 0.05, ** p ≤ 0.01.

Bp-WCV is classically formulated with the adjuvant alum and administered
intramuscularly in the human population. To determine if Bp-WCV provides crossprotection in a model more closely related to what is currently used in humans, and
determine if protection is adjuvant- or route-dependent, we re-formulated both Pa-WCV
and Bp-WCV with alum, and administered them intranasally and intraperitoneally. As a
control, we also tested the efficacy of acellular pertussis vaccine (Bp-ACV) administration
using both routes (intranasal and intraperitoneal). We observed that animals which had
received alum-only vaccination were heavily colonized in their upper and lower respiratory
tracts, as determined by quantification of colony forming units (CFU) in the nasal wash
and lung homogenate (Figure 13A, B). We observed that regardless of the route of
administration, the Pa-WCV led to a significant reduction of bacterial burden in both the
lung and nasal wash (Figure 13A, B). Consistent with our hypothesis that the Bp-WCV
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would induce cross protection when vaccines were administered with the adjuvant alum,
the groups which received Bp-WCV had a significant reduction of bacterial burden in both
the lung and nasal wash (Figure 13A, B). This cross-protection was not observed with the
acellular pertussis vaccine. Overall, Bp-WCV was protective against P. aeruginosa
regardless of the route of administration or the adjuvant formulation.
3.4.2 B. pertussis whole cell immunization induces protection in a β-ENaC murine
model
P. aeruginosa is known for its ability to cause difficult-to-treat antibiotic resistant infections
in the lung of patients with cystic fibrosis (CF) (94, 95). Vaccination against P. aeruginosa
could be particularly beneficial in these patients to reduce the burden of disease and
improve morbidity and mortality associated with P. aeruginosa infections. To determine if
the observations in outbred CD-1 mice also translate to a CF-like model, we used mice
overexpressing the β-ENaC receptor that display CF-like lung phenotypes (87), and
compared them to their C57BL/6 littermates. Mice were vaccinated with Pa-WCV, BpWCV, or the adjuvant alum intraperitoneally on days 0 and 21, and then challenged with
P. aeruginosa intranasally. Consistent with our findings in the wild-type CD-1 mouse
model, Pa-WCV was able to induce a protective immune response against acute P.
aeruginosa infection in both C57BL/6 and β-ENaC mice 14 hours post-infection (Figure
13C, D). In addition, Bp-WCV administration also significantly reduced P. aeruginosa
bacterial burden in the nasal wash in both strains (Figure 13D).
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Figure 13. Intranasal vaccination with P. aeruginosa and B. pertussis whole cell vaccines
adjuvanted with alum decreases bacterial burden in the respiratory tract of CD-1 (A, B),
C57BL/76 (C, D) and β-ENaC (C, D) mice, one day post infection. (Figure legend
continued on next page)
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(Figure 13 legend continued) Sixteen hours post challenge, groups of mice were
dissected and the bacterial burden in the lung (A, C) and nasal wash (B, D) were
quantified using serial dilution. Using whole body plethysmography prior to euthanasia,
tidal volume of breath (E) and inspiratory time (F) were quantified and compared to
baseline. Each dot represents an individual mouse, and error bars represent standard
error of the mean. Vertical dotted line separates genotypes of mice, horizontal dotted
line indicates the average value measured at baseline (E, F). In A-D, asterisks over bars
indicate comparison to alum-vaccinated control group. In E & F, asterisks over bars
indicate comparison baseline value for that group, asterisks over brackets indicate
comparison between groups and represent statistical significance determined by
ANOVA with Multiple comparisons: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
To further characterize the protective response and its impact on respiratory function, we
used whole-body plethysmograph (WBP) to calculate the tidal volume of the breath and
the inspiration time. This analysis revealed that infection significantly reduced the tidal
volume of breath (TVb) in non-vaccinated mice regardless of the strain. We observed that
vaccination with either Pa-WCV or Bp-WCV helped restore baseline TVb (Figure 13E).
Furthermore, we observed that the inspiration time (Ti), or time spent on inhaling, was
significantly increased in infected β-ENaC transgenic mice, but not C57B/6 mice,
compared to the non-challenged baseline (Figure 13F). Vaccination with either the PaWCV or Bp-WCV was able to resolve this increase and return Ti levels to non-challenged
baseline. Taken together, TVb and Ti data illustrate that P. aeruginosa infection lead to
longer, but shallower, breathing in mice, and that both Pa-WCV and Bp-WCV
administration restore this phenotype to baseline.
3.4.3 B. pertussis whole cell immunization induces the production of anti-P.
aeruginosa antibodies
One of the classical hallmarks of vaccine-induced immunity is the production of pathogenspecific antibodies following vaccination. In the case of P. aeruginosa, we recently
demonstrated that antibodies induced by Pa-WCV are a mechanistic correlate of
protection (32). We hypothesized that vaccination with Bp-WCV generates antibodies that
bind the surface of P. aeruginosa. To characterize the antibody response induced by each
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of these vaccine formulations, we used an ELISA to detect serum IgG binding to whole
P. aeruginosa bacteria. Mice that received the adjuvant alone, curdlan or alum, regardless
of the route of administration, did not produce detectable anti-P. aeruginosa antibodies
(Figure 14). However, vaccination using the Pa-WCV induced significant levels of anti-P.
aeruginosa IgG in the serum, regardless of the adjuvant, the route of administration, or
the strain of mice used. In addition, the Bp-WCV alone induced production of crossreactive anti-P. aeruginosa IgG in all these models, supporting our hypothesis (Figure
14). In contrast, Bp-ACV vaccination did not lead to the production of detectable anti-P.
aeruginosa antibodies.

Figure 14. P. aeruginosa and B. pertussis whole cell, but not acellular, immunizations
induce production of antibodies that bind whole P. aeruginosa. IgG serum titers were
determined by ELISA for CD-1 mice (A) and C57BL/6 WT or β-ENaC mice (B). Each
dot represents an individual mouse, and error bars represent standard error of the
mean. For samples in which no response was detected, the arbitrary value of 1 was
assigned. The asterisks over bar indicates comparison to adjuvant vaccinated,
brackets indicate comparison to other vaccinated group, and represent statistical

significance determined by ANOVA with Multiple comparisons: **** p ≤ 0.0001.

3.4.4 Bp-WCV cross-reactive antibodies bind OprF and GroEL
To gain insights into the targets recognized by the antibodies raised in response to BpWCV, we performed western blot analysis using P. aeruginosa whole cell lysate. We
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probed using pools of serum from mice that had been vaccinated with either the Pa-WCV,
the Bp-WCV, or the Bp-ACV (all adjuvanted with alum, administered intraperitoneally),
(Figure 15). We observed that Pa-WCV led to the production of antibodies binding to
numerous P. aeruginosa products and to bands forming a repetitive pattern, which we
speculate might be lipopolysaccharide. In contrast, Bp-WCV induced production of
antibodies that bound two defined antigens (Figure 15). In agreement with the ELISA
data, the Bp-ACV serum did not lead to the detection of P. aeruginosa by western blot
either.
To identify the P. aeruginosa antigens bound by antibodies triggered by Bp-WCV, we
performed immunoprecipitation and mass spectrometry. Immunoprecipitants were
formed by incubating the serum with whole P. aeruginosa lysate, and purifying antigenbound antibodies using mass-spectrometry compatible magnetic protein A/G beads. The
purified and eluted antigens were analyzed by mass spectrometry in the WVU Mass Spec
Core Facility, and identified peptides were mapped to PAO1 protein database (SwissProt
TaxID=208964). This analysis led to the detection of 10 proteins with 2 or more peptides

Figure 15. Immunoblot serum IgG antibody binding to P.
aeruginosa lysate. P. aeruginosa lysate was separated by
SDS-PAGE

and

transferred

to

PVDF

membrane.

Membranes were blocked, then separated for primary
incubation with pooled serum samples from vaccinated
groups, indicated beneath the blot image. Serum binding
was detected using anti-IgG antibodies, developed, and
imaged using Chemidoc Touch Imaging System (Bio-Rad).
Chemiluminsescent

images

colorimetric images of ladder.
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were

overlayed

onto

(Supplementary Table S4). The proteins were then sorted based on abundance and
percent coverage of the antigen, and the top two outer-membrane protein candidates
were selected for further analysis. The cross-reactive antigen candidates selected for
further testing were: GroEL (25 peptides, 48% coverage) and OprF (7 peptides, 30%
coverage). To identify if Bp-WCV-induced antibodies bind to either of these gene
products, we performed immunoblotting on two oprF transposon mutants from the
ordered PAO1 transposon mutant library and the parental PAO1 strain. GroEL was not
tested using this strategy as this protein is thought to be essential and no transposon
mutants with interruption in groEL are available (259, 262). We observed that serum from
Bp-WCV vaccinated mice reacted with a protein of approximately 60 kDa in the
transposon mutants and the parental PAO1 strain (Figure 16A). In addition, the serum
from Bp-WCV vaccinated mice also reacted with a protein of approximately 30 kDa in
parental PAO1, but the binding was not detected against the transposon mutant strains
containing an insertion in the gene oprF (Figure 16A).
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Figure 16. Serum antibodies in B. pertussis whole cell immunized mice bind to P.
aeruginosa OprF, which is homolog to B. pertussis OmpA. A. Immunoblot using pooled
Bp-WCV immunized serum against P. aeruginosa transposon mutant containing
insertion in oprF. B. Alignment of P. aeruginosa OprF and B. pertussis OmpA amino
acid sequences. C. Overlay of OprF and OmpA structures.

P. aeruginosa outer membrane protein OprF is a protein of 37 kDa with two domains, an
N-terminal 8-stranded beta-barrel domain which spans the outer membrane (20 kDa),
and a C-terminal globular OmpA domain (15 kDa subunits, 56 kDa total). To determine if
OprF has an ortholog in B. pertussis, we performed a pBLAST search of the whole OprF
amino acid sequence within the Bordetella taxid. This search resulted in alignment of the
OmpA domain of the P. aeruginosa OprF protein to the B. pertussis OmpA protein
(BP0943). We identified that there was a 46% identity between the amino acid sequences
of the two OmpA domains (Figure 16B). To further understand the similarity of these
proteins, we compared their structures. The structure of the OmpA domain of P.
aeruginosa OprF was previously solved using x-ray crystallography (PDB ID: 5U1H). As
the structure of the B. pertussis OmpA protein has not been solved, we utilized the
SWISS-MODEL homology modeling system to predict the structure and visualized it
using UCSF Chimera software (261, 263, 264). Overlay of the structures showed a high
structural homology between B. pertussis OmpA and the OmpA domain of P. aeruginosa
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OprF, which supports our hypothesis that this protein is one of the cross-reactive antigens
between B. pertussis and P. aeruginosa (Figure 16C).
Next, to identify the larger antigen observed via immunoblotting (Figure 15), we first
compared the molecular weight of the band observed (approximately 60 kDa) to the
proteins identified by immunoprecipitation and mass spectrometry. We observed that P.
aeruginosa GroEL had the highest number of peptides mapped during the mass
spectrometry analysis (25 peptides, 48% coverage) and a similar molecular weight (57
kDa). GroEL is a chaperonin highly conserved across Gram-negative bacteria including
Escherichia coli (80% identity) and highly antibiotic resistant bacteria such as the
ESKAPE pathogens (Figure 17A, B). GroEL is also highly abundant, primarily located in
the cytoplasm, but sometimes also embedded in the membrane (265–268). In the
absence of readily accessible purified P. aeruginosa GroEL, we performed
immunoblotting using the closely related E. coli GroEL to determine whether Bp-WCVinduced antibodies could bind GroEL. We observed that the Bp-WCV induced antibodies
were capable of binding purified E. coli GroEL, and that the band appeared similarly sized
to the previously observed (Figure 17C). P. aeruginosa GroEL has an ortholog in B.
pertussis (269, 270) with 76.33% identity at the amino-acid level (Figure 17D). When we
predicted the structure of these proteins using SWISS-MODEL homology modeling, both
were modelled based on the crystallized structure of GroEL from Xanthomonas oryzae
(PDB ID: 6KFV) (Figure 17e), and showed high structural similarity.

71

Figure 17. GroEL is a highly conserved bacterial protein, and can be bound by BpWCV induced serum antibodies. A. Alignment of P. aeruginosa and E. coli GroEL

amino acid sequences. B. GroEL amino acid sequence conservation in relevant
pathogenic bacteria. C. Immunoblotting of Bp-WCV serum to P. aeruginosa lysate and
recombinant GroEL. D & E. Sequence alignment and structure predictions for P.
aeruginosa and B. pertussis GroEL.
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3.4.5 Bp-WCV cross-reactive antibodies bind clinical P. aeruginosa isolates
The long-term objective of our laboratory is to develop a sub-unit vaccine for protection
against P. aeruginosa. One of the obstacles to surmount is the high antigenic variability
of isolates causing infection in patients. To explore whether antigens from B. pertussis
could provide protection against clinical P. aeruginosa isolates, we first determined the
sequence conservation of P. aeruginosa OprF and GroEL amongst 130 genomesequenced clinical strains from CF patients (74). We observed that both OprF was 100%
conserved across these isolates, and GroEL was 100% conserved in all but one clinical
isolate, where the GroEL protein contained a single amino acid replacement (V525M).
Binding of Bp-WCV serum to these isolates was then tested by both ELISA and western
blot (Table 2). With ELISA, we observed that the serum from adjuvant-only vaccinated
animals did not bind the clinical isolates while antibodies in the pooled Pa-WCV serum
bound each clinical P. aeruginosa isolates. Finally, there was consistent and significant
binding of antibodies in the Bp-WCV serum to each P. aeruginosa clinical isolate tested
(Figure 18A). Subsequent western blot analysis of IgG binding to whole cell lysates
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Figure 18. Bp-WCV induced serum antibodies bind clinical isolates of P. aeruginosa.
A. ELISA to quantify binding in pooled serum samples to clinical isolates of P.
aeruginosa. B. Western blot analysis of binding in pooled Bp-WCV serum to lab strain
PAO1 and clinical isolates of P. aeruginosa.

73

antigens, with molecular weights consistent with P. aeruginosa OprF and GroEL. In the
case of one clinical isolate, antibodies in the Bp-WCV reacted with a much larger number
of antigens. All together, these data indicate that antibodies raised in response to BpWVC vaccination recognize antigens in a wide variety of clinical P. aeruginosa isolates,
suggesting potential future applications for vaccine development (Figure 18B).
3.5

Discussion

In this report, we sought to determine the protective role of a B. pertussis whole cell
vaccine against the Gram-negative pathogen P. aeruginosa. We observed that Bp-WCV
induced a protective adaptive immune response against P. aeruginosa in CD-1, C57BL/6,
and transgenic β-ENaC mice. We further demonstrated that the Bp-WCV was able to
induce production of anti-P. aeruginosa IgG, and that they bind GroEL and OprF. These
proteins have homologs in Bordetella pertussis that we hypothesize are inducing crossprotection: GroEL and OmpA. Further, we demonstrated that these antigens are
conserved in clinical isolates of P. aeruginosa, as was antibody cross-reactivity.
The antigens identified in this study, GroEL and OprF, are known to be immunogenic and
antigenic proteins of P. aeruginosa. GroEL, which works in conjunction with the protein
GroES to form a well-characterized barrel-shaped chaperonin, is conserved amongst
many bacterial species (269–272). This bacterial protein is highly abundant and
immunogenic (265, 266). While some studies have shown GroEL from various species
can be protective as vaccine antigen and adjuvant in pre-clinical studies, GroEL from B.
pertussis failed to protect against infections caused by this microorganism in mice (273,
274). Efficacy of GroEL may be in part limited by the fact that this protein is primarily
expressed in the cytosol, although in some cases it can be surface-exposed (274, 275).
We observed that GroEL is highly conserved amongst Gram-negative bacteria of clinical
relevance. In addition, it is known that GroEL is similar to mitochondrial heat shock protein
Hsp60 (51.15% identity of Hsp60 to P. aeruginosa GroEL). While this characteristic might
be an advantage associated with cross-reactivity and potential protection against other
bacterial species, GroEL may not be a viable candidate vaccine antigen for vaccination
in humans due to potential undesired cross-reactivity (266). For example, an increase in
anti-P. aeruginosa GroEL antibody titers is observed in cystic fibrosis proceeding the
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onset of diabetes,

and is hypothesized to play a role in the mitochondrial stress

associated with diabetes (266). A similar phenomenon has been observed in the context
of Chlamydia pneumoniae infection, which is associated in increased titers of anti-Hsp60
IgG that correlate to myocardial infarction and coronary death following infection (161,
276). If GroEL is a protective antigen for P. aeruginosa, it would be necessary to further
analyze the epitopes recognized by the Bp-WCV induced cross-reactive antibodies to
identify specie-specific epitopes.
The other cross-reactive antigen identified in this study, OprF, is a highly abundant outer
membrane porin. OprF also plays significant roles in pathogenesis of P. aeruginosa, (161,
277). OprF is capable of transporting ions and low molecular-mass carbohydrates, such
as sodium chloride, glucose, and sucrose (278). OprF is vital in maintenance of the cell
membrane and regulation of cell morphology, quorum sensing, and virulence factors
including adhesion to eukaryotic cells, biofilm production, and type 3 secretion system
(277, 279–282). Deletion or functional knockout of the OprF gene in Pseudomonas
aeruginosa leads to decreased virulence in several infection models, including
Caenorhabditis elegans, cell culture, and mouse models (277, 283). OprF is also
overexpressed in anaerobic conditions, such as those mimicking CF-like lung phenotypes
(158). Various vaccines containing OprF have been pre-clinically and clinically tested for
efficacy (116, 284). One study found that dendritic pulsed with OprF induce a protective
response following adoptive transfer (157). Another group found that two peptides, linear
epitopes from the OmpA domain, conjugated to the carrier protein KLH were able to
induce a protective response in mice (11). A recombinant OprF-OprI vaccine was tested
in humans, and induced strong IgG and IgA antibody response (116). P. aeruginosa OprF
contains two domains, an N-terminal membrane embedded 8-fold beta-barrel porin, and
a C-terminal globular domain made of homo-4-mer known as the OmpA domain. While
the studies referenced above were focused on the beta-barrel domain of OprF, the
structure and sequence homology data obtained in this study seem to indicate that crossreactivity is potentially mediated via the globular OmpA domain of OprF. OmpA-family
proteins are produced by a wide variety of pathogenic and nonpathogenic bacteria,
including Haemophilus influenzae, Klebsiella pneumoniae, and Chlamydia trachomatis,
but not all species produce both domains found in the P. aeruginosa protein (161, 285).
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Further investigation, such as epitope mapping could be used to identify the protective
antigens for subsequent subunit vaccine formulation. Notably, we observed 100%
conservation of the OprF amino acid sequence in clinical isolates of P. aeruginosa,
suggesting that it could be a viable antigen for protection against a variety of strains of
the pathogen. In addition, P. aeruginosa produces several OmpA family proteins that
could likely be used for vaccination against this bacterium (286, 287). By examining the
conserved epitopes of OmpA domains, it may be possible to target multiple protein
antigens simultaneously.
This manuscript highlights that the non-specific effects of B. pertussis whole cell
vaccination could also provide protection against the respiratory pathogens P.
aeruginosa. However, the data shown here suggests that acellular pertussis vaccines do
not provide protection against P. aeruginosa. During the last thirty years, whole cell
pertussis vaccination has been replaced by acellular immunization in a large number of
countries, including the US. It is currently unknown whether protection against P.
aeruginosa mediated by Bp-WCV occurs in the human population. As the acellular-only
vaccinated population continues to age, follow-up studies examining the incidence of P.
aeruginosa infection in Bp-WCV and Bp-ACV populations will become feasible and will
help shed light on the potential clinical impact of our observations. In addition, future
studies focused on vaccination using the B. pertussis GroEL and OmpA proteins will
determine if these antigens are sufficient to induce protective immunity against P.
aeruginosa, and identify the epitopes involved in cross-reactivity.
Taken altogether, this manuscript illustrates that cross-reactivity amongst antigens in
vaccines and unrelated pathogens is a novel source for antigen identification, and that
some whole cell vaccines could have more uses than originally intended. Further
research is necessary to determine in the cross-reactive antigens are sufficient to induce
protection in an active or passive immunization model.
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4.1

Abstract

Pseudomonas aeruginosa is a highly antibiotic resistant Gram-negative opportunistic
pathogen for which there are no approved vaccines or immunotherapies. Vaccination
could be used in the highest risk populations for P. aeruginosa infections, such as patients
with the genetic disease cystic fibrosis or other immunocompromising conditions. We
hypothesize that bacterial components that are conserved in clinical isolates of P.
aeruginosa, highly expressed during infection, exposed, and important for pathogenesis
are protective antigens for vaccination against acute respiratory P. aeruginosa challenge.
To test this hypothesis, we selected antigens based on P. aeruginosa iron-acquisition
proteins FptA, PhuR, and HasR, and examined them in a model of vaccination and acute
challenge. Antigens were formulated either as peptides conjugated to a carrier protein, or
as proteins embedded in styrene-maleic acid co-polymers (SMALPs). Following
vaccination and boost, we performed a P. aeruginosa intranasal acute challenge and
quantified bacterial burden in the respiratory tract. Additionally, we characterized the
humoral response to immunization. We observed that these antigens were immunogenic,
but did not induce a significant reduction of bacterial burden following challenge.
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4.2

Introduction

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that is found
ubiquitously in the environment and is able to cause severe infections with high morbidity
and mortality. Respiratory infections by P. aeruginosa are prevalent in patients that have
the genetic disorder cystic fibrosis or are under assisted ventilation (288). In Europe in
2015, 13.7% of P. aeruginosa isolates were resistant to at least three antimicrobial
groups, and 5.5% were resistant to all five antimicrobial groups (289). In the United
States, multi-drug resistance strains of P. aeruginosa account for 13% of all strains
isolated (51, 237), and in some countries such as Pakistan the rate of multi-drug
resistance of P. aeruginosa clinical isolates has reached 22.7% in 2019 (89). Treatment
post disease-onset is becoming less feasible as antibiotic resistance continues to
increase, and vaccination could be viable tool in combatting P. aeruginosa infections.
While there are numerous vaccines for bacterial pathogens on the market and a
considerably large effort to develop one for P. aeruginosa, none has been approved for
use in the United States (94).
Whole cell vaccines for P. aeruginosa are protective in many laboratory models, but have
some significant drawbacks for use clinically. First, they can be highly reactogenic and
trigger local and systemic inflammation after administration (48). Whole cell vaccines
against P. aeruginosa also have limited efficacy against heterologous strains of the
pathogen, especially those with varied lipopolysaccharide serotypes (290). As a result of
these limitations, we instead sought to identify conserved antigens that can be formulated
into a subunit vaccine to target P. aeruginosa. To select antigens, we considered proteins
that are surface exposed, where they can be readily recognized by the immune system
(95). We then narrowed our selection to outer membrane proteins known to be upregulated during respiratory infection in mice compared to in vitro culture (291). A major
conclusion from our previous RNA-sequencing study was that several of the iron
acquisition system genes of P. aeruginosa were significantly upregulated during infection
(291). P. aeruginosa uses several differentially expressed iron-acquisition systems, which
allow it to adapt rapidly to new environments and uptake iron in either oxidation state as
well as if it is contained within heme (292, 293). Based on the RNA-seq data set, we
selected the iron acquisition system receptors fpvA (7.4 fold-change, p=4.19E-88), fptA
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(41.9 fold-change, p=5.8E-204), phuR (29.5 fold-change, p=1.5E-131), and hasR (78.8
fold-change, p=6E-150) (291) for further investigation (291).
Ferric iron (Fe3+) uptake occurs using extracellular chelating molecules called
siderophores. P. aeruginosa produces two siderophores: pyoverdine and pyochelin (294).
Pyoverdine is a green fluorescent siderophore that is produced by pseudomonads, and
is the compound primarily responsible for iron-uptake (295, 296). Pyoverdine is necessary
for P. aeruginosa to cause infection (297, 298). The siderophore pyochelin is produced
by P. aeruginosa and other pseudomonad species, in response to iron deprivation (292,
294). Each siderophore utilizes a TonB-dependent receptor on the surface of P.
aeruginosa, which allows for uptake of siderophores and xenosiderophores Pyoverdine
utilizes the ferripyoverdine receptor, FpvA (299, 300). The Fe(III)-pyochelin receptor,
FptA, is an outer membrane receptor of P. aeruginosa that binds the secreted pyochelin,
allowing for uptake of the siderophore and bound iron (301). PhuR and HasR are used
for heme acquisition, and are the Pseudomonas heme uptake (PhuR) and heme
acquisition system (HasR) receptors. PhuR binds heme directly, whereas HasR uses the
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hemophore HasAp (302). If both of these proteins are mutated or deleted, the P.
aeruginosa is severely attenuated and loses virulence (291, 294, 300–303).

Figure 19. Iron-acquisition systems of P. aeruginosa used as antigens in this report.
Iron is an essential nutrient and P. aeruginosa utilizes several mechanisms to acquire
it from its environment. Siderophores, pyoverdine and pyochelin bind ferric iron, and
then uptake occurs via the FpvA and FptA receptors, respectively. P. aeruginosa can
also acquire iron from heme molecules, using direct uptake via the PhuR receptor, or
using the hemophore HasAp and HasR receptor.
Vaccination against P. aeruginosa iron acquisition system antigens have been shown to
induce protection from the pathogen previously (141, 196, 304). We have demonstrated
that four peptides designed based on the ferripyoverdine receptor FpvA induced a strong
humoral response towards, and protection from P. aeruginosa (196). Specifically, we
used a model of mucosal immunization of keyhole limpet hemocyanin (KLH) conjugated
peptides with the adjuvant curdlan (26, 31, 196). Because FpvA, FptA, PhuR, and HasR
have complementary roles in nutrient acquisition and virulence of P. aeruginosa, we
sought to expand the vaccine to target them all simultaneously. Following the model we
developed using FpvA, we hypothesized that the iron acquisition system proteins FtpA,
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PhuR, and HasR would be immunogenic and protective from acute P. aeruginosa murine
pneumonia. We first designed peptides based on conserved regions of those proteins,
and tested immunogenicity and efficacy. From these studies, we identified the most
immunogenic peptides for each antigen and formulated a multivalent vaccine that targets
FpvA, FptA, HasR, and PhuR simultaneously. While we observed that peptides based on
each protein were immunogenic, they failed to induce a protective response in this model
of infection. Similar results were obtained when the antigens were formulated in styrene
maleic acid lipo-polymers (SMALP), indicating that these antigens are immunogenic, but
do not induce sufficient clearance of P. aeruginosa after challenge.
4.3

Materials & Methods

4.3.1 Bacterial strains and growth conditions
The P. aeruginosa PAO1 (Vasil) strain was grown on Pseudomonas Isolation Agar (PIA,
Becton Dickinson) at 36°C overnight. Bacteria were then swabbed off the plate,
resuspended in phosphate buffered saline (PBS), and the concentration was adjusted as
needed based on optical density (OD600). For challenge studies, bacteria were grown
overnight on lysogeny again (LA, Miller) at 36°C. A single colony was used to inoculate 3
mL of lysogeny broth (LB, Miller), and allowed to grow overnight at 36°C with orbital
shaking. The overnight culture was diluted 1:100 in fresh LB and grown until exponential
phase. Bacteria were centrifuged, and the pellet resuspended in sterile PBS, quantified
by OD600 and diluted to the challenge dose.
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4.3.2 Protein structure visualization and epitope design
We retrieved the structure of FptA (PA4221), which was previously solved by
crystallography and x-ray diffraction (PDB ID: 1XKW) (305). Homology modeling of P.
aeruginosa PhuR and HasR receptors were based on Serratia marcescens hemophore
receptor HasR (PDB ID: 3CSL; 19.73 and 27.34% sequence identity respectively) using
SWISS-MODEL. Summary of homology modelling results shown in in Table 3.
Table 3. Homology modeling results for P. aeruginosa proteins PhuR and HasR.
PAO1
Target

Structure
used
for
homology
modeling

PDB
ID

Global
Model
Quality
Estimation

%
Sequence
Identity

Sequence
similarity

Coverage

Range
(aa)

PhuR

Serratia
marcescens
HasR

3CSL

0.50

19.73

0.30

0.89

42-764

HasR

Serratia
marcescens
HasR

3CSL

0.34

27.34

0.34

0.82

49-723

Peptide antigens were designed as described previously in Sen-Kilic et. al. (196). Briefly,
we examined crystalized or predicted structures and identified extracellular peptides 1550 aa in length. To predict extracellular portions of the structure, we used the Orientations
of Proteins in Membranes (OPM) database (306). Hydrophobicity was calculated using
Kyte-Doolitle analysis in CLC Main Workbench, and also taken into consideration when
identifying outer membrane segments. Predicted outer membrane portions were then
screened for predicted B cell epitopes and potential homology with commensal bacteria
and host proteins. Ellipro and Bepipred were used to predict linear antibody and B cell
epitopes, and peptides were selected where the epitopes overlapped with extracellular
portions of the protein (307, 308). Using NCBI-BLASTp, we searched homology of
peptides to other bacteria, and peptides with total score superior to 50.0 when compared
to non-pathogenic commensal bacteria were excluded from the study to avoid any
potential undesired cross-species reactivity. Any peptides with higher than zero percent
identity to Homo sapiens proteins were excluded to reduce risk of cross-reactivity with the
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host. Six peptides were selected for each antigen, and then a cysteine residue was added
to the N-terminus for conjugation to carrier protein. Peptides were synthesized by
Biomatik USA. For quality control, 85% w/w purity was used as a cut-off. Each peptide
was conjugated to keyhole limpet hemocyanin (KLH) for immunogenicity studies.
Following immunogenicity studies, new preparations of immunogenic peptide were
conjugated to EcoCRM197 (genetically detoxified diphtheria toxin) by FinaBiosolutions
LLC. Unconjugated peptides were used for ELISA. Peptide sequences are listed in Table
4.
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Table 4. Peptides selected for synthesis and immunogenicity and efficacy studies. A cysteine
reside was added to each at the N-terminus prior to conjugation (not shown). Residues
highlighted in red had variants in the clinical isolates. Underlined resides are involved in ligand
binding.
Peptide ID

Location

Sequence

FptA-1

267-299

SITNMAGVPMAKDGSNLGLSRDTYLDVDWDRFK

FptA-2

331-367

RLRYAGSFGAIDPQTGDGGQLMGAAYK

FptA-3

392-432

ETRQDTARFLNLPNTPVNVYRWDPHGVPRPQIGQYTSPGTT

FptA-4

596-626

TYTSTEYLKDSQNDSGTRYSTFTPRHLLRLW

FptA-5

645-666

QAQSDYSVDYRGVSMRQGGYAL

FptA-6

687-711

NLFDRTYYQSLSNPNWNNRYGEPRS

PhuR-1

268-301

TDQKSAYGGPYDKGKPAIPPSMLPGGMYQWRKGN

PhuR-2

391-427

HQKVTGMRSGTGTNLDTGADSPRDALERSSDFPDPTV

PhuR-3

509-543

GFRTPTAKALYGRFENLQAGYHIEPNPNLKPEKSQ

PhuR-4

566-598

KYRDFIDEDALNTDSTGGNGQTFQSNNIERAVI

PhuR-5

666-697

TLVKRKDRVDDSTFHTPDGTASQFKTPGFGVL

PhuR-6

715-755

LYNLTDKKYWLWDDVRGYDSVGEASALAPANIDRLSQPGRN

HasR-1

317-352

HLGDYDPGTKGSIGELRTGAWFNPEAGQRVKHSPVA

HasR-2

386-407

YDDANMLNTENQALWEKLGSSD

HasR-3

436-458

DNRNRQQTLQRGITPGYSITYQT

HasR-4

549-580

RLRGDTGFNARTFILGTTRQTDMPLQYAVDRE

HasR-5

619-633

ITGRPHGGGAENMYP

HasR-6

684-697

MQPPGYGMAGIGNS
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4.3.3 Clinical isolates of P. aeruginosa
Clinical isolates of P. aeruginosa, described by Burns et al. (74), were kindly provided by
Dr. Robert Ernst. To quantify conservation of the selected peptides, we used CLC Main
Workbench version 20. The PAO1 fptA, phuR, and hasR gene sequences were aligned
to sequences from 130 clinical isolates.
4.3.4 Styrene maleic acid lipo-polymer (SMALP) antigen formulation.
SMALP antigens were prepared and purified as described by Centola et al., 2020 (309).
Briefly, SMALPs containing either PAO1 wild-type HasR or PhuR were made using
Escherichia coli containing a recombinant plasmid, then following expression induction,
cells were lysed, and the HasR-SMALP or PhuR SMALP were collected by affinity
purification and concentration determined. “Empty” SMALP were used as control, and
contained the same scaffold, but contained no protein.
4.3.5 Immunogenicity & challenge studies
Peptide vaccines were formulated to include 35 µg of each peptide.

The curdlan

adjuvanted vaccines were formulated as previously described in our laboratory and
include 200 μg of curdlan in a total volume of 40 µL (26, 196). SMALP vaccines contained
50 µg of the antigen. As control for SMALP antigen vaccines, we vaccinated with the flowthrough SMALP products from purification, which contained no tagged membrane
proteins. Because the SMALPs are made using pieces of the extracellular membrane,
they may contain endotoxin, which could have adjuvant-like properties. We used Limulus
amebocyte lysate (LAL) test (Thermo Scientific Pierce LAL Chromogenic Endotoxin
Quantitation Kit ) to quantify endotoxin in both the SMALP antigens end and administered
equivalent amounts of endotoxin in the empty SMALP control.
Groups of 6-week-old female CD1 mice were used for each vaccination study. Vaccines
were administered either intranasally (IN) or intramuscularly (IM). Mice were anesthetized
using 76 mg ketamine/kg body weight and 7.6 mg xylazine/kg body weight, then slowly
pipetting the total volume of 40 µL of vaccine onto the nares of the animal. Intramuscular
vaccination was performed by injecting the vaccine into the right hindlimb of the animal,
using a sterile 29-gauge needle. Animals were monitored during recovery. Vaccines were
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administered on day 0 and again on day 21. On day 34, mice were anesthetized and 27x107 CFU of PAO1 were administered intranasally. At 16 hours post infection, animals
were euthanized by IP injection of euthasol (39 mg of pentobarbital). Blood was drawn
via cardiac puncture, and then tissues were aseptically dissected. Nasal wash and lung
were collected for quantification of bacterial burden by serial dilution and plating on PIA.
All murine experiments were approved by West Virginia University Institutional animal
Care and Use Committees (WVU-ACUC1606003173) and done in accordance with
National Institutes of Health Guide for the care and use of laboratory animals.
4.3.6 Serology
To quantify antibody response, we assessed anti- PAO1, total peptide, and individual
peptide titers by ELISA. Blood isolated via cardiac puncture at 1-day post-challenge was
centrifuged at 14,000 x g for 2 minutes and the supernatant serum was saved at -80°C
until analysis. Pierce high-binding 96-well plates were coated with 50 µL of antigen
overnight at 4°C, then washed three times with 200 µl of PBS-Tween 20 (PBS-T).
Antigens tested include P. aeruginosa (2x107 CFU/well), cocktail of peptides (1µg/mL of
each peptide), and individual peptides (1µg/mL). Following coating, plates were blocked
with 200 µl of 2% Bovine Serum Albumin (BSA) and incubated at 4°C overnight and then
washed three times with PBS-T. Serum samples were loaded at a dilution of 1:50 in 2%
BSA and then serially diluted in 2% BSA. The serum coated plates were incubated 2
hours at 37°C, washed four times with PBS-T, then detected with 100 µl 1:2,000 anti-IgG,
-IgM, or -IgA (SouthernBiotech) secondary antibodies conjugated to alkaline
phosphatase. After one-hour incubation at 37°C with detection antibody, each well was
washed five times with PBS-T. To develop, 100 µl Pierce p-Nitrophenyl Phosphate
(PNPP) solution (Thermo Fisher Scientific) was added to each well. Plates were
developed in the dark at room temperature for 30 minutes, and the optical density at
405nm was determined using a SpectraMax® i3 plate reader. Titers were determined by
selecting the highest dilution at which the absorbance was twice as high as the
absorbance of the negative control (31, 196).
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4.3.7 Statistical analysis
Statistical analyses were performed using GraphPad Prism version 7 (GraphPad). The
group comparisons were analyzed by one-way ANOVA (analysis of variance) with
Tukey’s multiple-comparison test unless otherwise stated. Unpaired Student’s t-test were
used for comparisons of two samples. ROUT test was used to identify outliers from
datasets, which were then excluded from analysis.
4.4

Results

In this work, we sought to formulate a protective vaccine for P. aeruginosa using the outer
membrane proteins and iron acquisition receptors FptA, PhuR, and HasR. We examined
three outer membrane iron acquisition system receptors, FptA, PhuR, and HasR. We
identified peptides for vaccination, quantified conservation of these peptides in clinical
isolates of P. aeruginosa and tested for efficacy. We identified which of the designed
peptides were immunogenic, and tested an 11-valent vaccine containing immunogenic
FpvA, FptA, PhuR, and HasR peptides.
4.4.1 FptA peptide design and immunogenicity
The Fe(III)-pyochelin outer membrane receptor FptA is an outer membrane protein of P.
aeruginosa that acquires iron via the pyochelin siderophore. It contains 665 amino acid
residues, is 76.23 kDa in size, and forms a 22-stranded beta barrel connected by 11
extracellular loops at the C-terminal end, and an N-terminal cork-like domain. Together
these form a hydrophobic core where pyochelin can be bound (305). After examining the
structure (PDB ID: 1XKW), we identified the outer membrane loops, predicted linear
epitopes, and selected 6 peptides for conjugation to KLH and use for immunogenicity
studies (Figure 20A). We next examined the conservation of the amino acid sequence at
each of the peptide locations in a collection of 133 clinical isolates (Figure 20B-G). FptA1 is an extracellular loop that contains N271, a residue involved with binding pyochelin
(305). Of the clinical isolates we examined, 93.79% encoded an identical FptA-1 peptide
sequence (Figure 20B), but the remaining 6.21% had a single amino acid substitution
(S282A). Examining conservation of FptA-2, we found that 41.08% contained the same
sequence as that in PAO1, 57.81% had a M352T substitution, and 1.11% had a D342E
substitution (Figure 20C). Next, FptA-3 was conserved in 98.44% of clinical isolates, but
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there were two clinical isolates that contained single amino acid changes (R399P and
P404S) and retained the conserved Q395, a residue that binds to pyochelin (305) (Figure
20D). FptA-4 was conserved in 100% of the clinical isolates (Figure 20E) while FptA-5
was conserved in 99.22% of the clinical isolate except for one strain with a
S658Dsubstitution (Figure 20F). Finally, FptA-6 was conserved in 99.22% of the clinical
isolate and with one strain with a S698F substitution (Figure 20G). Both variants of FptA6 have a conserved W702, which is a residue involved in binding of FptA to pyochelin
(305). Overall, we observed that the selected peptides were either identical to the PAO1
peptide sequence, or contained a single amino acid substitution.
Peptides were conjugated on the N-terminal to the carrier protein KLH via a cysteine

Figure 20. FptA peptide design and conservation in clinical isolates. A. FptA structure
(PDB ID: 1XKW). B. Selected peptides for immunogenicity studies, overlayed on the
amino acid sequence of FptA. C. FptA structure with selected peptides shown in blue
overlay. D-I. Conservation of each peptide sequence in clinical isolates of P.
aeruginosa.
residue. We then formulated a 6-valent FptA peptide vaccine containing equimasses of
each peptide, combined with the adjuvant curdlan, and tested efficacy in a model of
mucosal vaccination and challenge. Following vaccination and boost, P. aeruginosa was
administered intranasally and efficacy examined 14 hours later. We did not observe any
significant changes in bacterial burden in the lung or nasal wash following vaccination
with the hexavalent FptA-KLH vaccine, compared to mice which were adjuvant-only
vaccinated (Figure 21A, B). However, we did observe a significant increase in the anti-P.
aeruginosa IgG titers, and anti-peptide cocktail titers in the peptide-vaccinated mice
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compared to adjuvant-only controls (Figure 21C, D). To identify which of the six peptides
in the vaccine were immunogenic, we performed ELISA to quantify titers of antibodies
towards each of the peptides individually, summarized in Figure (Figure 21 E). Using
these data, we selected peptides 1, 4, 5, and 6 for use in subsequent vaccine formulations
(Figure 21F).

Figure 21. Efficacy and immunogenicity of FptA-KLH hexavalent vaccine. One day
post-challenge, animals were euthanized, blood was drawn, and respiratory tissues
were dissected, homogenized, diluted, and plated to quantify colony forming units
(CFU) (A-B). C-E. Anti-whole bacteria and -peptide IgG titers were quantified in the
blood. F. FptA peptides 1, 4, 5, and 6 were selected to move forward for multi-valent
vaccine formulation. The asterisks over bars indicate comparison to NVC, and
represent statistical significance determined by student t-test: **** p ≤ 0.0001.
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4.4.2 PhuR peptide design and immunogenicity
The next target for vaccination we selected was PhuR (PA4710), which is one of P.
aeruginosa’s outer membrane heme uptake receptors. PhuR contains 764 amino acids
and is 84.7 kDa in size. The structure of this protein has not been solved, and we therefore
utilized a structure based on homology modelling of PhuR to the S. marcescens heme
acquisition receptor, using SWISS-MODEL homology modeling. The model predicts a
barrel-protein similar to the other iron-acquisition systems that have been examined here
(Figure 22A). Concordantly, we selected peptides which were located in the extracellular
loops of the predicted structure, and examined their conservation in clinical isolates.
PhuR-1, PhuR-3, and PhuR-5 were conserved in 99.21% of clinical isolates, but for each
peptide there was one clinical isolate strain that contained a single amino acid mutation
(Figure 22B, D, F). In peptide PhuR-2, 97.63% encoded a sequence identical to PAO1,
but 2.36% of clinical isolates contained an amino acid 397 substitution (Figure 22E).
Peptides PhuR-4 and PhuR-6 were 100% conserved. Peptides were then conjugated to
the carrier protein KLH, mixed in equal amounts, and tested in the model of acute P.
aeruginosa infection. We observed that there were slight, but not significant decreases in
the CFU in the lung and nasal wash (Figure 23A, B). There was a significant increase of
anti-PAO1 serum IgG production, and high production of total peptide binding IgG (Figure

Figure 22. PhuR peptide design and conservation in clinical isolates. A. PhuR predicted
structure. B. Selected peptides for immunogenicity studies, overlayed on the amino
acid sequence of PhuR. C. PhuR structure with selected peptides shown in blue
overlay. D-I. Conservation of each peptide sequence in clinical isolates of P.
aeruginosa.
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23C, D). We then examined the antibody response to the individual peptides and
observed binding to PhuR-2, PhuR-4, and PhuR-5 (Figure 23E, F). For subsequent
formulations of the multivalent vaccine, PhuR-2, PhuR-4, and PhuR-5 were used,
because these were the most immunogenic of the PhuR peptides, and were well
conserved in the clinical isolates.

Figure 23. Efficacy and immunogenicity of PhuR-KLH hexavalent vaccine. One day
post-challenge, animals were euthanized, blood was drawn, and respiratory tissues
were dissected, homogenized, diluted, and plated to quantify colony forming units
(CFU) (A-B).C-E. Anti-whole bacteria and -peptide IgG titers were quantified in the
blood serum. F. PhuR peptides 2, 4, and 5 were selected to move forward for multivalent vaccine formulation, and are shown here in green. The asterisks over bars
indicate comparison to NVC, and represent statistical significance determined by

student t-test: **** p ≤ 0.0001
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4.4.3 HasR peptide design and immunogenicity
HasR (Heme acquisition system receptor) is the other most predominant heme
acquisition receptor of P. aeruginosa, and utilizes hemophore HasAp for heme
acquisition. The structure of this protein has not been resolved, so we also utilized
homology modelling based on the highest identity sequence, S. marcescens HasR
(Figure 24A). We first identified the predicted extracellular regions, then predicted linear
epitopes. From these, we screened for homology with commensal bacterial proteins and
human proteins. Then we selected 6 candidate peptide sequences for vaccination. Next,
we examined homology of these peptides within HasR of clinical isolates of P.
aeruginosa. Notably, four of the six peptides we selected, HasR-2, 3, 5, and 6, were
conserved in 100% of the clinical isolates we examined (Figure 24C, D, F, G). Peptide
HasR-1 was conserved in 98.45% of clinical isolates, but 2 clinical isolates contained a
A352T amino acid substitution (Figure 24B). Finally, peptide HasR-4 was conserved in
96.12% of clinical isolates, but 3.87% (5 clinical isolates) contained an amino acid
substitution (P572S) (Figure 24G). Consistent with our previous analysis of peptide

Figure 24. HasR peptide design and conservation in clinical isolates. A. HasR predicted
structure. B. Selected peptides for immunogenicity studies, overlayed on the amino
acid sequence of HasR. C. HasR structure with selected peptides shown in blue
overlay. D-I. Conservation of each peptide sequence in clinical isolates of P.
aeruginosa.
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conservation, the HasR peptides selected were highly conserved. Clinical isolate peptides
were either identical to the PAO1 peptides or contained a single amino acid substitution.
The six HasR peptides were then conjugated to the carrier protein KLH and formulated
into a hexavalent vaccine with the adjuvant curdlan, and tested for immunogenicity and
efficacy against acute P. aeruginosa challenge. HasR-KLH vaccination resulted in a slight
decrease in the bacterial burden in the lung tissue one day post-infection, and a significant
decrease in bacterial burden in the nasal wash (Figure 25A, B). Interestingly, we did not
observe binding of IgG to whole P. aeruginosa, but did observe binding to the peptide
cocktail. Antibodies were primarily binding to two of the HasR peptides: HasR-2 and
HasR-5 (Figure 25C-F) which were selected for the multivalent formulation.

Figure 25. Efficacy and immunogenicity of HasR-KLH hexavalent peptide vaccination.
One day post-challenge, animals were euthanized, blood was drawn, and respiratory
tissues were dissected, homogenized, diluted, and plated to quantify colony forming

units (CFU) (A-B). C-E. Anti-whole bacteria and -peptide IgG titers were quantified in
the blood serum. F. HasR peptides 2, 4, and 5 were selected to move forward for multivalent vaccine formulation, and are shown here in green. The asterisks over bars
indicate comparison to NVC, and represent statistical significance determined by
student t-test: * p ≤ 0.05, *** p ≤ 0.001
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4.4.4 Multivalent peptide vaccine immunogenicity and protection
Our lab has previously demonstrated that a peptide-based vaccine for FpvA was
efficacious (196). However, we sought to add additional antigens to this formulation, to
reduce risk of vaccine-driven bacterial evolution and further improve efficacy. While
peptide based FptA, PhuR, and HasR vaccines on their own provided insufficient
protection on their own, we hypothesized that the co-administration of the most
immunogenic peptides from each vaccine would induce stronger protection. To test this
hypothesis, we selected 2-4 peptides from each of the antigens, based on
immunogenicity, and formulated them into an 11-valent vaccine. The peptides selected
were as follows: FpvA-2, FpvA-4, FptA-1, FptA-4, FptA-5, FptA-6, PhuR-2, Phu-4, PhuR-

Figure 26. Efficacy of 11-valent vaccination against P. aeruginosa. One day postchallenge, animals were euthanized, blood was drawn, and respiratory tissues were
dissected, homogenized, diluted, and plated to quantify colony forming units (CFU) (AB). C-E. Anti-whole bacteria and -peptide IgG titers were quantified in the blood serum.
The asterisks over bars indicate comparison to adjuvant only vaccinated, and
represent statistical significance determined by ANOVA with Multiple comparisons: ***
p ≤ 0.001, **** p ≤ 0.0001
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5, HasR-2, and HasR-5. These eleven peptides, conjugated to KLH, were formulated with
the adjuvant curdlan and delivered intranasally or intramuscularly, as indicated in the
figures.
The 11-valent iron acquisition peptide vaccine was administered on day 0, and boosted
on day 21, prior to a P. aeruginosa challenge at day 34. One day post-challenge, we
determined efficacy and investigated the serological response to immunization. There
was not a significant reduction of bacterial burden in either the lung or nasal wash,
regardless of whether the vaccine was administered intranasally or intramuscularly
(Figure 26A, B). We observed that the 11-valent vaccine was able to induce the
production of both anti-P. aeruginosa and anti-peptide serum IgG (Figure 26C, D). AntiPAO1 titers were similar to those observed for each of the single-receptor vaccines we
tested previously. While we did not observe any differences in anti-P. aeruginosa titer
when altering the route of immunization, IM-vaccinated animals had significantly higher
anti-peptide cocktail titers. We also observed that the response to each peptide in the
vaccine was still detectable when they were administered together (Figure 26E). Overall,
we observed that the 11-valent vaccine was immunogenic and able to induce production

Figure 27. Efficacy of 11-valent-CRM vaccination against P. aeruginosa. One day
post-challenge, animals were euthanized, and the respiratory tissue homogenized,
diluted, and plated to quantify colony forming units (CFU) (A-B). Additionally, anti-P.
aeruginosa IgG titers were quantified by ELISA. The asterisks over bars indicate
comparison to adjuvant only vaccinated, and represent statistical significance
determined by ANOVA with Multiple comparisons: **** p ≤ 0.0001
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of anti-PAO1 antibodies. However, the 11-valent vaccine was not able to induce sufficient
protection against respiratory P. aeruginosa challenge.
One of the tools that can be used to increase recognition of peptide antigens for
vaccination is use of alternative carrier proteins (310). Considering that KLH is not an
FDA-approved carrier, we reformulated the 11 immunogenic peptides with the carrier
protein EcoCRM197. Unpublished data and observations from our laboratory indicate that
CRM-conjugation boosts the antibody response to peptides, in comparison to KLH
conjugation. Similarly to our previous experiment, the 11 CRM-conjugated peptides were
formulated into a vaccine with the adjuvant curdlan and vaccinated either intramuscularly
or intranasally before challenge with P. aeruginosa. One day post-challenge, we
evaluated protection by quantifying CFU in the lung and nasal wash. With CRMconjugated peptides, we observed neither a significant level of protection nor significant
induction of anti-PAO1 IgG titers (Figure 27).
4.4.5 HasR and PhuR SMALP vaccine immunogenicity
Following our observation that peptides, while immunogenic, did not induce protection
from P. aeruginosa infection, we sought to test the antigens as whole proteins. Membrane

Figure 28. Efficacy and immunogenicity of heme-acquisition system SMALP antigens
for vaccination. One day post-challenge, animals were euthanized, and the respiratory
tissue homogenized, diluted, and plated to quantify colony forming units (CFU) (A-B).
C. anti-P. aeruginosa IgG titers were quantified by ELISA. The asterisks over bars
indicate comparison to adjuvant only vaccinated and brackets compare between
groups. Asterisks represent statistical significance determined by ANOVA with Multiple
comparisons: ** p ≤ 0.01, **** p ≤ 0.0001
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proteins can be difficult to use in vaccines, due to their insolubility and likelihood to be
contaminated with endotoxin. Here, we used the heme-acquisition system receptors
PhuR and HasR inserted into styrene-maleic acid lipo-polymer (SMALP) nanodiscs (309).
Each nanodisc is embedded with one receptor, and was then purified by affinity
purification. By embedding the receptors in a scaffold, it solubilizes the membrane
proteins, making them much easier to purify, and displays the proteins in a near native
confirmation, potentially displaying structural epitopes (311). SMALPs containing either
HasR or PhuR were purified and formulated into individual or combined PhuR & HasR
containing vaccines. As a negative control, we quantified the endotoxin in each
preparation of SMALP antigen, and administered an equivalent endotoxin amount of
empty SMALP. After immunization and boost, animals were challenged, and efficacy was
determined day one post infection (Figure 28). We observed that the empty SMALP
control group was heavily colonized by P. aeruginosa in both the lung and nasal wash
(Figure 28A, B). Further, neither of the individual or the combined SMALP formulations
tested induced a significant reduction of bacterial burden (Figure 28A, B). Interestingly,
the SMALP vaccines were able to induce production of significant titers of anti-PAO1 IgG
in the blood serum (Figure 28C). Indeed, anti-PAO1 titers in SMALP-vaccinated animals
were higher than what we observed in any of the peptide-vaccinated animals. Despite
this, the SMALP vaccines were not able to induce protection against acute P. aeruginosa
infection.
4.5

Discussion

We previously formulated a P. aeruginosa vaccine containing 4 peptides based on the
outer loops of FpvA, and found that it was able to induce protection against P. aeruginosa
(196). We have also shown that antibodies are necessary for protection from P.
aeruginosa in a model of mucosal vaccination and challenge (32). In this report, we
systemically designed and tested vaccines targeting the iron acquisitions systems of P.
aeruginosa: FptA, PhuR, and HasR. We predicted immunogenic peptides based on
extracellular loops of each protein, linear-epitope prediction models, and conservation of
the sequences in clinical isolates. We formulated hexavalent vaccines targeting each of
the proteins, and tested them independently in an intranasal model of immunization and
challenge. We observed that, while animals were able to produce antibodies in response
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to each vaccination, not all of the peptides were immunogenic, and the formulations were
unable to induce a protective response against P. aeruginosa.
Following this, we reformulated a vaccine to contain the 11 most immunogenic peptides
we tested, including 2-4 peptides targeting FpvA (196), FptA, PhuR, and HasR. This 11valent vaccine was again able to induce a strong anti-peptide antibody response, but low
levels of anti-P. aeruginosa IgG, and was not protective. One common concern with
increasing number of antigens contained in a vaccine is dilution of the antibody response,
and previously antigenic components no longer being recognized. We observed that
antibodies from 11-valent vaccinated mice were still able to recognize all 11 of the
peptides. Subsequently, we repeated the experiment using peptides conjugated to
EcoCRM197, but found that this was also not sufficient to induce protection. Finally, we
tested use of SMALPs containing PhuR or HasR proteins, as well as co-administration of
the two, and it was immunogenic but not protective.
Our findings indicate that, while these peptides and proteins were immunogenic, they are
not sufficient for formulation of an effective vaccine for P. aeruginosa in this model.
Immunization targeting iron acquisition systems has had varied success with other
pathogens. Vaccination using siderophore-protein conjugates is protective against
uropathogenic E. coli (UPEC) infection (312, 313). Vaccination of cattle against E.
coli O157:H7 siderophore-receptor and porin proteins is able to reduce bacterial burden
in fecal samples of cows prior to processing for beef, thus reducing risk of food-borne
illness (314). Transferrin and lactoferrin receptor proteins were efficacious in protecting
against Neisseria meningitidis infection, but did not move forward in clinical testing due
to antigenic variation in clinical isolates (315–317). Active and passive immunization
against the OmpW protein of Acinetobacter baumannii, which is involved in iron
acquisition for the bacterium, is protective (318, 319). Within the field of P. aeruginosa
vaccinology, there has been considerable variation in efficacy of iron-acquisition antigen
vaccines (320). We have demonstrated efficacy of an FpvA-KLH vaccine previously,
which was protective in a model of acute pneumonia challenge. Others have
hypothesized that Th17-inducing antigens, FpvA and HasR included, will be necessary
for design of an efficacious vaccine (141). Directly contradicting this, a group showed that
the outer membrane protein OprH, but neither FpvA nor HasR were protective antigens
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for P. aeruginosa vaccination (119). The iron acquisition systems of P. aeruginosa are
also being considered for use as targets for therapeutics. Taking advantage of the
bacterial need for iron, gallium(III)-salophen molecules, which mimic heme, can be used
to inhibit bacterial iron and heme acquisition systems, therefore decreasing virulence
(309). These data taken together highlight the importance of immune targeting of iron
acquisition systems. While it was not sufficient in this model, further research to optimize
immunogenicity may improve protection.
Moving forward and considering future formulations of subunit vaccines for P. aeruginosa,
there are several possible solutions to consider. First is the abundance of these proteins
on the outer membrane of P. aeruginosa. While we, and others, have shown that they are
expressed at higher levels during infection and iron starvation, the total amount present
on the cell surface may not be sufficient for immune recognition during infection (291). If
too few of the epitopes are expressed, antibodies targeting them may not be sufficient.
This is consistent with our observation of low levels of binding to P. aeruginosa by ELISA.
We have previously demonstrated that anti-P. aeruginosa IgG correlate highly with
protection induced by P. aeruginosa whole cell vaccination, and that B cells are a
mechanistic correlate of protection (31, 32). Low levels of anti-P. aeruginosa titers may
be a result of low expression of the antigens, given that we observed high levels of antipeptide and protein titers. In the future, as a control, we could additionally quantify antiprotein titers using purified FptA, PhuR, and HasR proteins, in order to determine whether
antibodies from peptide-immunized mice are able to bind the full protein. This may provide
insight on how to improve formulation of these antigens. An additional solution to improve
protection induced by these vaccines is to combine iron-acquisition system antigens with
other, highly abundant outer membrane proteins.
Another factor to consider is the immunogenicity of the vaccine formulation.
Immunogenicity can be impacted by the structure of the antigens, and we currently do not
know the secondary structure of the peptides we tested. They may be in a conformation
that is inaccessible to antibodies, preventing them from binding to native protein. We also
do not know the conjugation efficacy and ratio to the carrier proteins, and this could be
further investigated and optimized to improve response. The adjuvant included in the
formulation can also influence immunogenicity (10). Here, peptide vaccines were
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adjuvanted with curdlan, which we have previously used (26, 32, 196). Alternative
adjuvants, such as MF59 and AS04, both of which are FDA approved, may increase the
antibody production in response to vaccination and boost efficacy of these vaccines (23,
321–323). We initially tested immunogenicity in an intranasal model of immunization, but
we also utilized intramuscular vaccination with the multivalent vaccine formulation.
Intranasal immunization induces a mucosal and Th17-skewed immune response, and
production of IgA antibodies (31, 234). However, mucosally delivered vaccines, especially
soluble subunit vaccines, also tend to be less immunogenic than those delivered
parenterally (324). Given that we did not observe protection in intranasally immunized
animals, and low levels of antibody production, we considered alteration of the
immunization method. The intramuscular route is more clinically relevant and is able to
induce a stronger systemic immune response, which we hypothesized would increase the
efficacy of our experimental vaccine (325). IM vaccinated mice did have increased antipeptide titers, but there was not an increase in anti-pathogen titer. This alteration alone
was not sufficient to boost response to a protective level, but should still be considered
with future formulations.
Development of a vaccine against P. aeruginosa is a goal that will require comprehensive,
systemic analysis of antigens and adjuvants that induce protection. While these
experiments do not support the hypothesis that FptA, PhuR, and HasR are protective
antigens alone, our findings indicate that they are immunogenic and could be considered
for future multivalent vaccines. Moving forward, it is vital that we consider antigens which
are highly expressed during infection as well as those that are abundant on the cell. This
could be accomplished by performing immunopeptidomics using serum from protected
animals and immunoprecipitation to identify immunogenic bacterial antigens. Further
screening to quantify the total amount of antigens present could also increase likelihood
of immune recognition of the whole bacteria. The significant need for a subunit P.
aeruginosa vaccine remains and should be further investigated. These data will not only
help prevent P. aeruginosa infections, but could influence formulations of vaccines for
other bacterial pathogens in the future.
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Chapter 5. Discussion
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Pseudomonas aeruginosa is a highly adaptable pathogen which can cause a variety of
infections. P. aeruginosa infections are highly prevalent in patients with cystic fibrosis,
who suffer recurrent and chronic P. aeruginosa infections throughout their lifetime (179,
326). It is highly antibiotic resistant, and therefore, a vaccine to prevent P. aeruginosa
infections is of utmost importance (94). Here, we sought to understand P. aeruginosa
vaccinology, in order to formulate vaccines that could be tested further in laboratory and
clinical tests. In chapter two, we examined whole cell immunization against P. aeruginosa
and the respiratory pathogen Bordetella pertussis (31). This parallel analysis of whole cell
immunization revealed distinct correlates of protection for each pathogen. In chapter
three, we demonstrated the cross-protective immune response induced by the Bp-WCV
to protect from P. aeruginosa murine pneumonia. Using immunoprecipitation, mass
spectrometry, and immunoblotting, the cross-reactive antigens were identified as GroEL
and OprF. Finally, in chapter four, our previously tested vaccine development platform
for targeting the iron acquisition systems of P. aeruginosa, was expanded to target three
novel antigens: FptA, PhuR, and HasR (196). Using conjugated peptides and SMALP
nanodiscs, we tested formulations of multivalent vaccines for immunogenicity and efficacy
against acute P. aeruginosa challenge. This chapter selectively discusses the
implications of these works, with a focus on the future of vaccine development for P.
aeruginosa.
5.1

Vaccine-mediated correlates of protection

Vaccines are a vital tool in the medical field for prevention of infection by deadly
pathogens, and have saved countless lives world-wide in the century they have been
used widely. For many vaccines, there are correlates of protection (CoP) that have been
used to measure and compare effectiveness between batches and generations of
formulations (38). CoP are broadly and subjectively defined as any biological factor that
correlates to protection, but even the measurement of what constitutes protection varies
depending on the pathogen of interest. Protection can be measured in death rate,
bacterial burden or clearance, or other physiological health measures. Here, we
functionally defined a correlate of protection as any measurement for which there was a
significant linear correlation to bacterial burden in the respiratory tract. This model utilized
data per biological replicate, and did not take into consideration the vaccine which animals
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had received, but compared each biological correlate directly to bacterial burden. In our
model, we do not achieve sterilizing immunity, but we did observe whole cell vaccine
induced reduction of bacterial burden. We observed unique CoP for Pa-WCV and BpWCV induced protection from their respective pathogens. In the future, these factors can
be taken into consideration when measuring CoP for next generation vaccines (32).
The CoP for P. aeruginosa acute murine pneumonia infection were:


Reduction in lung weight



Reduction in blood lymphocytes and neutrophils



Reduced cytokines IL-6, TNF-α, KC/GRO, and IL-10 in the lung supernatant



Increased anti-P. aeruginosa serum IgG antibodies



Increased IFN-γ in the lung supernatant

The CoP for B. pertussis acute murine pneumonia infection were:


Increased anti-B-pertussis serum IgG antibodies



Reduced TNA- in the lung supernatant



Reduced neutrophils in the lung

It should be noted that these correlates are not an exhaustive list, and may be specific to
this model of immunization and challenge. The correlates we identified should be further
scrutinized and tested as mechanistic CoP, which means the measured factor directly
causes protection (33). It is important to note that CoPs are unique to each vaccine
formulation and each animal model. CoPs we identified may be specific to the type of
infection model used: acute pneumonia. Unique correlates may be identified for other
types of infections, including chronic pneumonia, burn wounds, surgical wounds, otitis,
and keratitis, and will likely vary depending on antigen and adjuvant formulation. In the
future, use of alternative infection models could be considered, and CoPs should be
validated for those models.
Further work is necessary to determine if the CoP have predictive ability, and are clinically
translational (327). It is not always possible or feasible to perform human challenge
studies or to sample human bacterial burden over time, but non-invasive, clinically
translational biomarkers should be examined and tested for use as substitute endpoints.
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For example, CXCL13 is a cytokine induced during germinal center formation, that can
also be detected in murine and human serum samples (328). CXCL13 was not quantified
in these studies, but should be considered in the future as a CoP and biomarker for
protection for both P. aeruginosa and B. pertussis.
5.2

Nonspecific effects of whole cell immunization

Whole cell vaccines are considered a crude formulation because they contain killed or
inactivated cultured bacteria, but they induce complex immune responses that are not
fully understood (34, 329, 330). As we understand more about whole cell vaccinemediated immune responses, it has become increasingly appreciated that whole cell
vaccines can induce long-lasting immune memory that is not pathogen specific (243,
246). In Chapter 3, we examined this in the context of inducing an adaptive immune
response to an unrelated bacterium through production of cross-reactive antibodies (239,
244, 245). However, whole cell vaccines can also cause long-lasting epigenetic
reprogramming of innate immune cells which impact their future response to infection,
which is known as trained immunity (251, 253, 331). This can occur in cells including
monocytes and macrophages, and allows for a quicker response to exposure to a
different pathogen (250–252). Trained immunity is a phenomenon that has been
observed in the context of several widely used whole cell vaccines, including the BCG,
DTP, and MMR vaccines (254). The BCG vaccine for Mycobacterium tuberculosis is
used in many countries where TB is still prevalent, and modulates the innate immune
response to induce protection against non-mycobacterium species and some types of
cancers (250–253).
A systematic review performed by the World Health Organization claims that the collective
improvement in outcomes in following vaccination with the three whole cell immunization
listed above is too strong to be a result of reduced incidence of only those infections (332).
These findings have huge implications on the impact of vaccinations on overall health
outcomes on humans, and should be further studied. We observed that the Bp-WCV
induced a protective response against P. aeruginosa, but we identified that one of the
cross-reactive antigens is GroEL, a protein which has high homology to a human protein
Hsp60 (270). In considering the development of GroEL as an antigen for vaccination,
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measures to prevent cross-reactivity would need to be adopted, including identification of
protective antigens that are pathogen specific and not homologous to epitopes in Hsp60.
In fact, production of anti-GroEL antibodies during P. aeruginosa infection has been
linked to development of CF-diabetes mellitis (266).

Other infections have been

correlated to development of allergy and autoimmune diseases, including Coxiella
burnetii and autoimmune liver disease, varied microbial infections and rheumatoid
arthritis, and coxsackievirus and myocarditis (333–335). Group A Streptococcus infection
can cause an array of post-streptococcal autoimmune disorders, including damage to the
central nervous system (336). Possible mechanisms include antibody cross-reactivity
between similar epitopes, as well as epitope spreading, non-specific activation of immune
cells, and development of superantigens (337). It is possible, and probable, that whole
cell vaccines can also induce damaging non-specific effects, because of cross-reactivity
of antigens in the cultured bacteria to human antigens. Cross-reactivity induced by whole
cell immunization may be a contributing factor to the reactogenicity associated with whole
cell vaccines, including the pertussis vaccine (36, 48). Currently, research does not
indicate that the risk of cross-reactivity is high enough to remove whole cell immunizations
from use clinically, but it is something to consider when formulating future generations of
vaccines (338).
5.3

Outer membrane proteins as vaccine antigens

In this dissertation, several outer membrane proteins were considered as antigens for P.
aeruginosa vaccination. Outer membrane proteins are ideal candidates for vaccine
antigens because they are surface displayed on the cell, and could have important roles
in the pathogenesis of the bacterium. We observed that the Bp-WCV induced protection
from P. aeruginosa, and hypothesize that this was primarily a result of cross-reactive
antibodies binding the outer membrane protein OprF. OprF is highly immunogenic and
has been tested as a vaccine antigen for P. aeruginosa previously, but the focus of prior
studies has been on the N-terminal beta-barrel domain (116, 164). Our data suggest that
the cross-reactivity is likely due to homology within the OmpA domain of OprF. The OmpA
domain of P. aeruginosa is also immunogenic and protective in other vaccination models.
A cowpea mosaic virus delivered recombinant OmpA vaccine induced protection from
heterologous serotyped strains of P. aeruginosa and enhanced phagocytosis by
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neutrophils in vitro (339). Additionally, there have been monoclonal antibodies developed
to target this domain (340). In future studies, we can assess the use of pertussis OmpA
protein to induce protection from P. aeruginosa challenge. Antigens which can provide
broad protection from pathogenic bacteria could also be used to develop monoclonal
antibodies, which could be used as alternatives for antibiotics. If we observe that Bp-WCV
induced cross-protection is a result of GroEL cross-reactivity rather than OmpA, which
we cannot rule out as of now, further research about the subcellular location of P.
aeruginosa and antigenicity of the protein would be necessary.
This dissertation presented data that use of peptide-immunization targeting outer
membrane proteins involved in iron acquisition was immunogenic but did not produce
sufficient immunity from P. aeruginosa. We individually tested FptA, PhuR, and HasR,
then combined immunogenic peptides for each of those with peptides based on FpvA.
Our formulation of 11 peptides targeting the four membrane proteins did not induce a
significant reduction of bacterial burden following challenge. This finding directly
contradicted our previous findings, where intranasal administration of FpvA-KLH
conjugates were protective in our model (196). The main rationale we considered for use
of peptide immunization in this model was increased solubility in comparison to
membrane-embedded proteins, and decreased potential for cross-reactivity with host
proteins. The peptides we selected are portions of predicted linear epitopes within the
external loops of the proteins, and do not have defined or predicted secondary structure.
We hypothesized that this would help to maintain solubility of the peptides and improve
their formulation as antigens. When we observed that these linear epitopes were not
sufficient to induce protection, we hypothesized that structural epitopes may play a more
important role. To assess this, we tested whole protein antigens embedded in SMALP
nanodisc carriers, but we still were unable to induce sufficient reduction of bacterial
burden. This indicates that, while those epitopes are still immunogenic, the antigens we
tested are not sufficiently protective. While we have previously shown that FptA, PhuR,
and HasR are upregulated during infection in comparison to when they are grown on lab
media, we do not have quantitative measurements of the proteins on the surface of the
cell. In the future, we could consider using mass spectrometry to identify the antigens of
highest abundance to identify antigens that may induce stronger protection from P.
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aeruginosa. Additionally, this platform for antigen identification could be adapted and
considered for other bacterial pathogens of interest, including Bordetella pertussis and
Borrelia burgdorferi.
5.4

Vaccine formulation and optimization

One caveat to the use of subunit vaccines, including peptide-based vaccines is the
immunogenicity of antigens (10, 196). We have previously shown that peptides alone are
not highly immunogenic, but attachment of the carrier protein KLH improved antibody
response (196). In this dissertation, peptides targeting three iron acquisition system
antigens were conjugated to two carrier proteins: keyhole limpet hemocyanin (KLH) and
detoxified diphtheria toxin (CRM197). Neither formulation was sufficient to induce anti-P.
aeruginosa response. One potential drawback to the use of peptides as vaccine antigens
is batch-variation within the peptides and within the conjugation to the carrier protein. To
test this in the future, several batches of peptides, from different manufacturers, could be
compared. Rather than conjugation to a carrier protein, the peptides could be synthesized
as a polypeptide chain, and conjugated to a carrier protein, to ensure equivalent antigen
presentation. Additionally, we should consider alternative adjuvants for our formulation.
Here we used two adjuvants: alum and curdlan. Curdlan is a β-1,3-glucan molecule used
as an adjuvant for mucosal immunization (20, 26, 341). In chapter 2, we found that it was
an effective adjuvant for both the P. aeruginosa and B. pertussis whole cell vaccines. For
this reason, we selected it for use while optimizing the peptide vaccine formulations in
chapter 5. However, curdlan is not an FDA-approved adjuvant. There are several FDAapproved adjuvants that could be tested in the future, including AS04, CpG, and MF59
(22, 23, 342, 343).
5.5

Conclusions and outlook for future of vaccine development for P. aeruginosa

The works performed and described in this dissertation were important steps in
identification of correlates of protection for P. aeruginosa whole cell immunization, and
identification and testing of antigens for subunit vaccination against P. aeruginosa. The
results obtained in this dissertation will help in the future development of vaccines against
P. aeruginosa and other relevant human pathogens.
The primary findings of this work were:
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Curdlan adjuvanted, intranasally delivered whole cell vaccines for Pseudomonas
aeruginosa and Bordetella pertussis are protective against acute pneumonia
challenge for each pathogen, respectively.



The B. pertussis whole cell vaccine induces a cross-protective response towards
P. aeruginosa, and induces binding to two P. aeruginosa proteins: GroEL and
OprF.



Peptide and SMALP based vaccines targeting the P. aeruginosa iron acquisition
system receptors FptA, PhuR, and HasR are immunogenic, but not protective from
acute P. aeruginosa murine pneumonia.

These data are highly valuable to the fields of Pseudomonas and Pertussis vaccinology,
and should be considered in future works towards formulations of vaccines. In future
studies, the cross-protective antigens identified should be tested as antigens in a subunit
vaccine. Once protective subunit vaccines are identified, they should be formulated into
a multivalent subunit vaccine, and the adjuvants and route of immunization should be
optimized to ensure strong, long-lasting antibody response towards P. aeruginosa
infections.
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Chapter 7. Appendix
Supplementary Table S1. Flow cytometry antibodies used to identify immune cells in the
lung.
Cell Marker

Fluorophore

Vender

Part #

CD11b

BB515

BD Biosciences

564454

Ly-6G and Ly-6C (GR-1) PE

BD Biosciences

553128

CD45R/B220

APC-Cy™7

BD Biosciences

552094

CD3e

BV510

BD Biosciences

563024

F480

PerCP Cy 5.5

Biolegend

123128

CD11c

efluor 450

eBioscience

48-0114-80

Supplementary Table S2. Flow cytometry antibodies used to identify T cell populations.
Cell Marker

Fluorophore

Vender

Part #

CD4

APC-Cy7

Biolegend

100526

CD8

PerCP-Cy5.5

BD Biosciences

551162

GATA3

APC

Miltenyi Biotec

130-100-650

RoRγT

PE-CF594

BD Biosciences

562684

T-bet

PE

BD Biosciences

561265
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Supplementary Table S3. Cytokines measured in the lung supernatant 16 hours post
challenge, using MSD Proinflammatory cytokine kit. Data in the table represent the mean
cytokine response ± standard error of the mean. Results are shown in pg/ml. Statistical
analysis was performed in GraphPad Prism, using one-way ANOVA with multiple
comparisons, and p-values are indicated for each comparison.

150

A-B

A-C

A-D

A-E

B-C

B-D

B-E

C-D

C-E

D-E

0.0084

0.9918

>0.999

0.0254

0.9993

0.9998

0.1239

0.0524

0.9962

IL-10

1.9283 ± 0.6352 1355.2888 ± 415.105 596.5443 ± 394.1773

0.1764 ± 0.1384

0.1286 ± 0.0624

0.0071

0.5341

>0.999

>0.999

0.2181

0.0407

0.0407

0.7273

0.7272

>0.999

4.2475 ± 1.1548

0.3025 ± 0.0841

0.6533

0.6743

>0.999

>0.999

>0.999

0.8028

0.8026

0.8237

0.8236

>0.999

0.0002

0.4914

0.0493

0.3109

0.0037

0.07

0.1342

0.7666

0.8042

IL-12p70

IL-1ß

60.2845 ±

11476.2441 ±

12304.5083 ±

19.1864

8618.3649

9964.1535

50.2831 ±

16684.4057 ±

12281.7448 ±

16.4161

2607.4902

2286.3586

challenged

0.9992

vaccinated,

10.7974 ± 9.3296

challenged

0.7095 ± 0.2871 118.293 ± 33.9908 1992.6022 ± 720.7802 258.4744 ± 188.4248

vaccinated,

IFN-γ

Challenged

E. Bp-WCV

B. pertussis

D. Adjuvant-

C. Pa-WCV

P. aeruginosa

B. Adjuvant-

vaccinated, Non-

A. Adjuvant-

Supplementary Table S3

4718.825 ± 2479.5007 8428.775 ± 1387.4776 <0.0001

IL-2

1.4703 ± 0.4768 454.5557 ± 368.7702 292.2783 ± 209.7871

0.1151 ± 0.0722

0.0446 ± 0.0166

0.4751

0.867

>0.999

>0.999

0.953

0.7426

0.6706

0.955

0.9363

>0.999

IL-4

0.9373 ± 0.3235 25.3238 ± 18.7449

7.6398 ± 2.2451

0.0031 ± 0.0015

0.0018 ± 0.0005

0.2865

0.9804

>0.999

>0.999

0.6463

0.4611

0.4611

0.9859

0.9859

>0.999

IL-5

1.4117 ± 0.4483 73.3711 ± 39.9675

134.6884 ± 101.5211

0.0602 ± 0.0258

0.0433 ± 0.0151

0.8393

0.3387

>0.999

>0.999

0.9197

0.9144

0.9143

0.5416

0.5415

>0.999

421386.8852 ±

157572.669 ±

132156.4975 ±

83738.2111

72346.3302

85821.7289

42.1712 ± 31.6675

<0.0001

0.2702

0.6061

>0.999

0.0247

0.0399

0.0014

0.9988

0.4802

0.736

16.7884 ±

132435.2572 ±

13263.8001 ±

2389.5116 ±

8.0416

32818.3028

7051.9568

1295.8402

66.3652 ± 29.976

<0.0001

0.9712

>0.999

>0.999

0.0002

0.0004

0.0003

0.9939

0.9873

>0.999

10.2121 ±

20365.6824 ±

8961.3718 ±

3.5782

4440.4497

5003.2764

0.0022

0.1764

>0.999

>0.999

0.3213

0.0176

0.0158

0.4095

0.3845

>0.999

1382.354 ± 1051.1864 0.5919

0.8633

>0.999

0.063

0.99

0.7737

0.5558

0.9383

0.3322

0.1527

IL-6

KC/GRO

TNF-α

IL-17

47.2789 ± 17.92

4.7426 ± 1.8512 605.4077 ± 252.2253 404.5358 ± 171.0921

389.9891 ± 166.3134 168.6643 ± 87.3674

14.9896 ± 3.903

1

Supplementary Table S4. Mass spectrometry revealed ten potential cross-reactive P. aeruginosa antigens bound by BpWCV induced antibodies.

Gene

Ensemble

symbol

Gene

Description

Coverage %

# Peptides

groEL

PA4385

60 kDa chaperonin [OS=Pseudomonas aeruginosa PAO1]

48

25

oprF

PA1777

outer membrane porin F [OS=Pseudomonas aeruginosa PAO1]

30

7

atpA

PA5556

ATP synthase subunit alpha [OS=Pseudomonas aeruginosa PAO1]

11

4

hupB

PA1804

DNA-binding protein HU-beta [OS=Pseudomonas aeruginosa PAO1]

50

3

rplP

PA4256

50S ribosomal protein L16 [OS=Pseudomonas aeruginosa PAO1]

23

3

atpD

PA5554

ATP synthase subunit beta [OS=Pseudomonas aeruginosa PAO1]

7

3

oprI

PA2853

major outer membrane lipoprotein [OS=Pseudomonas aeruginosa PAO1]

25

2

oprL

PA0973

peptidoglycan-associated lipoprotein [OS=Pseudomonas aeruginosa PAO1]

17

2

rplR

PA4247

50S ribosomal protein L18 [OS=Pseudomonas aeruginosa PAO1]

21

2

6

2

ornithine carbamoyltransferase, catabolic [OS=Pseudomonas aeruginosa

arcB

PA5172

PAO1]
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